CLINICAL TRIAL PROTOCOL  
PROTOCOL TITLE  A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, 
Tolerability, and Pharmacokinetics of PRAX -944 in Adults 
with Essential Tremor  
PROTOCOL NUMBER  PRAX-944-221 
COMPOUND NUMBER  PRAX-944 
CLINICAL TRIAL PHASE  Phase 2  
SPONSOR NAME  Praxis Precision Medicines Australia Pty Ltd  
SPONSOR ADDRESS  727 Collins Street Docklands Vic 3008, Australia  
REGULATORY AGENCY IDENTIFIER NUMBER(S) N/A 
CURRENT VERSION DATE  Version 6.0 – 11 August 2021 
CONFIDENTIALITY STATEMENT  
The information contained in this document is confidential and privileged to personnel directly involved in the conduct of the clinical trial. Any distribution, copying, or disclosure is strictly prohibited unless such disclosure is required by applicable laws and regulations. Persons to whom the information is disclosed must know that it is confidential.  
NCT Number-  [STUDY_ID_REMOVED]PR~ S 
PRECISION MEDICINES 
Praxis Precision Medicines Protocol PRAX-944-221 , Version 6.0 
SIGNATURE PAGE FOR SPONSOR 
Protocol Title: A Phase 2 Clinical Trial Evaluating the Efficacy , Safety , Tolerability , and 
Pha1macokinetics of PRAX -944 in Adults with Essential Tremor 
Clinical Trial o: PRAX-944-221 
Current Version Date: Version 6.0 -11 August 2021 
This clinical trial protocol was subject to critical review and has been approved by the 
appropriate protocol review committee of the Sponsor. The infmmation contained in this 
protocol is consistent with: 
• The cmrent risk-benefit evaluation of the study diug . 
• The ethical and scientific principles governing clinical reseaTch as set out in the 
Declaration of Helsinki , and the principles of the International Council for 
Ha1monisation (ICH) , and local country regulations . 
The Investigator will be supplied with details of any significant or new findings , including 
adverse events (AEs) , relating to treatment with the study diug . 
IIDocuSigned by: 
0 SignerName:-
1 Signing Reason I approve this docume nt 
Signing Time : 15-A ug-2021 I 21 :36:04 EDT 15-Aug-2021 I 21:36:08 EDT 
.. - I • 4A0B814E683880247E02 
MD,MS Date 
Confidential Page 2 of84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 3 of 84 INVESTIGATOR’S AGREEMENT 
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure,  and 
any other produc t information provided by the Sponsor. I agree to conduct thi s clinical tr ial in  
accorda
nce with the requirements of this protoc ol, and also to protect the rights, saf ety, privacy, 
and wel l-being of clinical trial participants in accordance with the following: 
•The ethic
al principles that have their origin in the Decla ration of Helsinki.
•International Council for Harmoni sation, E6 Good Clinical Practice: Consolidated
Guideline.
•All applicable laws and regulations.
•This document contains confidential information from the Sponsor, which may not be
disclosed to anyone other than clinical trial staff and members of the IRB/IEC.
Printed Name of Investigator  
Signature of Investigator  
Date 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 4 of 84 CONTACT INFORMATION IN CASE OF EMERGENCY  
Table  1: Emergency Contact Information  
Role in Clinical Trial  Name  Address and Telephone Number  
Responsible Physician , MD, PhD  One Broadway, 16th Floor  
Cambridge, MA 02142, USA  
Telephone: +1 617 504 3087  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 5 of 84 PROTOCOL SUMMARY TABLE  
DOCUMENT HISTORY  DATE  
Version 1.0  11 January 2019 
Version 2.0  07 November 2019  
Version 3.0  18 July 2020  
Version 4.0  20 October  2020 
Version 5.0  13 July  2021 
Version 6.0  11 August 2021  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 6 of 84 TABLE OF CONTENTS  
SIGNATURE PAGE FOR SPONSOR  ........................................................................................ 2  
INVESTIGATOR’S AGREEMENT  ........................................................................................... 3  
CONTACT INFORMATION IN CASE OF EMERGENCY  ....................................................... 4  
PROTOCOL SUMMARY TABLE  ............................................................................................. 5  
TABLE OF CONTENTS  ............................................................................................................ 6  
LIST OF TABLES  .................................................................................................................... 10  
LIST OF FIGURES  .................................................................................................................. 10  
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  .............................................. 11  
1. PROTOCOL SUMMARY  ...................................................................................... 14  
1.1. Synopsis ................................................................................................................. 14  
1.2. Study Schema  ......................................................................................................... 28  
1.3. Schedule of Activities  ............................................................................................. 29  
2. INTRODUCTION .................................................................................................. 38  
2.1. Background and Clinical Trial Rationale  ................................................................ 38  
2.2. Benefit/Risk Assessment  ........................................................................................ 39  
2.3. Known Potential Benefits  ....................................................................................... 39  
2.4. Known Potential Risks ............................................................................................ 39  
3. OBJECTIVES AND ENDPOINTS  ......................................................................... 41  
3.1. Part A  ..................................................................................................................... 41  
3.2. Part B  ..................................................................................................................... 42  
4. INVESTIGATIONAL PLAN ................................................................................. 45  
4.1. Overall Design  ........................................................................................................ 45  
4.1.1.  Screening/ Baseline Period  ..................................................................................... 45  
4.1.2.  Intervention Period  ................................................................................................. 46  
4.1.3.  Safety Follow -up Period  ......................................................................................... 48  
4.1.4.  Clinical Trial Duration  ............................................................................................ 48  
4.2. Scientific Rationale for Clinical Trial Design  .......................................................... 48  
4.3. Justification for Dose  .............................................................................................. 48  
4.4. Clinical Trial Committees  ....................................................................................... 49  
4.5. End of Clinical Trial Definition  .............................................................................. 49  
5. POPULATION ....................................................................................................... 50  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 7 of 84 5.1. Number of Participants  ........................................................................................... 50  
5.1.1.  Part A  ..................................................................................................................... 50  
5.1.2.  Part B  ..................................................................................................................... 50  
5.1.3.  Participant Replacement  ......................................................................................... 50  
5.2. Inclusion Criteria  .................................................................................................... 50  
5.3. Exclusion Criteria  ................................................................................................... 51  
5.4. Lifestyle Considerations  ......................................................................................... 52  
5.4.1.  Meals and Dietary Restrictions  ............................................................................... 52  
5.4.2.  Activity Restrictions  ............................................................................................... 53  
5.4.3. Contraception ......................................................................................................... 53  
5.4.4.  Sperm and Ova Donation ........................................................................................ 54  
5.5. Screen Failures  ....................................................................................................... 54  
6. CLINICAL TRIAL INTERVENTION  ................................................................... 55  
6.1. Study Drug(s) Administered  ................................................................................... 55  
6.1.1.  Part A  ..................................................................................................................... 55  
6.1.2.  Part B  ..................................................................................................................... 55  
6.2. Preparation/Handling/Storage/Accountability ......................................................... 57  
6.3. Randomization and Blinding................................................................................... 57  
6.3.1. Breaking the Blind  .................................................................................................. 57  
6.4. Study Drug Compliance  .......................................................................................... 57  
6.5. Concomitant Therapy  ............................................................................................. 58  
6.5.1.  Prohibited Medications  ........................................................................................... 58  
6.5.2. Permitted Medications  ............................................................................................ 59  
6.6. Dose Modification .................................................................................................. 59  
6.7. Intervention After the End of the Clinical Trial  ....................................................... 59  
7. DISCONTINUATION OF STUDY DRUG AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ................................................................ 60  
7.1. Discontinuation of Study Drug  ............................................................................... 60  
7.1.1.  Temporary Discontinuation  .................................................................................... 60  
7.1.2.  Rechallenge  ............................................................................................................ 60  
7.2. Participant Discontinuation/Withdrawal from the Clinical Trial  .............................. 60  
7.3. Lost to Follow -Up .................................................................................................. 60  
8. CLINICAL TRIAL ASSESSMENTS AND PROCEDURES  .................................. 62  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 8 of 84 8.1. Efficacy Assessments  ............................................................................................. 62  
8.1.1.  TETRAS  ................................................................................................................ 62  
  
  
8.1.4.  Quality of Life in Essential Tremor Questionnaire (QUEST; Part B Only)  .............. 65  
  
  
8.2. Safety Assessments ................................................................................................. 65  
8.2.1.  Physical Examinations  ............................................................................................ 65  
8.2.2.  Vital Sign Measurements  ........................................................................................ 65  
8.2.3.  Electrocardiograms  ................................................................................................. 66  
8.2.4.  Clinical Safety Laboratory Assessments  ................................................................. 66  
8.2.5.  Columbia- Suicide Severity Rating Scale (C -SSRS) Measurements  ......................... 67  
8.3. Pharmacokinetic Assessments ................................................................................. 67  
8.4. Adverse and Serious Adverse Events  ...................................................................... 67  
8.4.1.  Time Period and Frequency for Collecting AE and SAE Information  ...................... 67  
8.4.2.  Method of Detecting AEs and SAEs  ....................................................................... 67  
8.4.3.  Follow- up of AEs and SAEs  ................................................................................... 68  
8.4.4.  Regulatory Reporting Requirements for SAEs  ........................................................ 68  
8.4.5.  AEs of Special Interest  ........................................................................................... 68  
8.4.6.  Pregnancy  ............................................................................................................... 68  
8.4.7.  Disease -Related Events and/or Disease- Related Outcomes Not Qualifying as 
AEs or SAEs  .......................................................................................................... 69  
8.5. Exploratory Biomarkers  .......................................................................................... 69  
8.6. Treatment of Overdose  ........................................................................................... 69  
8.7. Genetics .................................................................................................................. 69  
8.8. Health Economic s/Medical Resource Utilization and Health Economics  ................. 69  
9. STATISTICAL CONSIDERATIONS  .................................................................... 70  
9.1. Sample Size Determination  ..................................................................................... 70  
9.2. Populations for Analyses  ........................................................................................ 70  
9.3. Statistical Analyses  ................................................................................................. 70  
9.3.1.  Efficacy Analyses  ................................................................................................... 71  
9.3.2.  Safety Analyses  ...................................................................................................... 71  
----
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 9 of 84 9.3.3.  Pharmacokinetic Analyses  ...................................................................................... 71  
9.3.4.  Other Analyses  ....................................................................................................... 71  
9.3.5.  Interim Analyses  ..................................................................................................... 72  
10. REGULATORY, ETHICAL, AND CLINICAL TRIAL OVERSIGHT 
CONSIDERATIONS  .............................................................................................. 73  
10.1.  Regulatory and Ethical Considerations .................................................................... 73  
10.2.  Financial Disclosure  ............................................................................................... 73  
10.3.  Informed Consent Process  ...................................................................................... 73  
10.4.  Data Protection  ....................................................................................................... 74  
10.5.  Data Q uality Assurance  .......................................................................................... 74  
10.6.  Source Documents  .................................................................................................. 75  
10.7.  Clinical Trial Files and Retention of Records  .......................................................... 75  
10.8.  Clinical Trial and Site Closure  ................................................................................ 76  
10.9.  Clinical Study Report  ............................................................................................. 76  
10.10.  Publication Policy  ................................................................................................... 76  
11. REFERENCES  ....................................................................................................... 77  
12. APPENDICES  ........................................................................................................ 79  
APPENDIX 1. CLINICAL LABORATORY EVALUATIONS  .............................................. 79  
APPENDIX 2. ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND REPORTING  ..................... 80  
APPENDIX 3. ACCEPTABLE BENZODIAZEPINES FOR CONCOMITANT USE  ............ 84  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 10 of 84 LIST  OF TABLES  
Table 1:  Emergency Contact Information  ............................................................................... 4  
Table 2:  Schedule of Activities (SoA) – Part A  ..................................................................... 30  
Table 3:  Schedule of Activities (SoA) – Part B  ..................................................................... 33  
Table 4:  Study Drug Information  .......................................................................................... 56  
LIST OF FIGURES  
Figure 1:  Study Schema  ......................................................................................................... 28  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 11 of 84 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
Abbreviation Definition  
ADL  activ ities of daily living  
AE adverse event  
AKI acute kidney injury  
ALT  alanine aminotransferase  
API active pharmaceutical ingredient  
AST  aspartate aminotransferase  
AUC 0-tau area under the concentration vs time curve from the time of dosing through 
the dosing interval  
  
  
BMI  body mass index  
BUN blood urea nitrogen  
Ca2+ Calcium  
CBC  complete blood count  
  
  
  
CI confidence interval  
CIOMS  Council for International Organizations of Medical Sciences  
CKD- EPI Chronic Kidney Disease Epidemiology Collaboration 
CL/F  apparent systemic clearance follow ing oral administration 
Cmax maximum observed concentration 
CNS  central nervous system  
CRF  case report form  
CSR  clinical study report  
C-SSRS Columbia -Suicide Severity Rating Scale 
CYP  cytochrome P450  
ECG  electrocardiogram  
eCRF  electronic case report form  
EEG  electroencephalogram  
ET essential tremor  
D
D• -
• --
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 12 of 84 Abbreviation Definition  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice 
HBsAg  hepatitis B surface antigen  
HCV hepatitis C virus  
IB Investigator’s Brochure  
ICH International Council for Harmonisation 
ICF Informed Consent Form  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
KDIGO  Kidney Disease Improving Global Outcomes  
KIM -1 kidney injury molecule -1 
MedDRA  Medical Dictionary for Regulatory Activities  
MR modified release 
NREM  non-rapid eye movement  
P-gp P-glycoprotein 
  
PK pharmacokinetic 
PT preferred term  
QAM  every morning 
QUEST  Quality of Life in Essential Tremor Questionnaire  
RBC  red blood cell  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SCr serum creatinine 
SD standard deviation  
SoA Schedule of Activities  
SOC  system organ class  
SUSAR  suspected unexpected serious adverse reaction  
t½  apparent terminal elimination half -life 
TEAE treatment -emergent adverse event  
TETRAS  The Essential Tremor Rating Assessment Scale  
Tmax time to maximum observed concentration 
-
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 13 of 84 Abbreviation Definition  
TRG  Tremor Research Group  
ULN upper limit of normal  
Vd/F  apparent volume of distribution after non- intravenous administration  
WBC  white blood cell  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 14 of 84 1. PROTOCOL SUMMARY  
1.1. Synopsis  
This is a brief summary of the clinical trial. For complete details, refer to the body of the 
protocol.  
PROTOCOL TITLE  
A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of 
PRAX -944 in Adults with Essential Tremor  
RATIONALE  
Essential Tremor (ET) is one of the most common neurological disorders with a prevalence of 
nearly 1%. It is characterized by a 6 to 12 Hz postural a nd kinetic tremor. Tremor typically 
occurs in the hands, arms, head, and voice, and is less common in the face, legs, and trunk. E T, 
by definition, is not associated with other neurological signs, although a resting tremor and impairments in balance, particularly tandem gait, have been described. The diagnosis of ET is 
based on medical history and neurological exam as described in The International Parkinson and 
Movement Disorders Society Consensus Statement on the Classification of Tremors.  
There is a rang e in the  severity of ET; some patients require no treatment, whereas others have 
severe disability with impairment in activities of daily living (ADLs) such as dressing and eating. 
Treatments for ET include pharmacological therapies, regional injection of botulinum toxin 
(off-label usage), and surgical therapies for those with severe disability. The most effective 
pharmacological therapies are propranolol and primidone. They have limited efficacy, with about 
50% of patients having a durable yet incomplete response. Dose -limiting side effects are 
common and include bradycardia for propranolol, and sedation and dizziness for primidone. Surgical therapies, including deep brain stimulation and ablation of the nucleus ventralis intermedius of the thalamus, are ef fective but they are reserved for medically refractory patients 
due to the risks associated with brain surgery. Many patients who are eligible for surgical therapies do not elect to have these procedures. Thus, there is a high unmet need for efficacious 
and well -tolerated pharmacological therapies for ET.  
While the genetics and pathophysiology of ET is not fully understood, it is thought to involve 
abnormal activity of cerebellar afferent and efferent pathways. This network consists of input 
from the inferi or olive to the cerebellar cortex, and outflow through deep cerebellar nuclei to the 
ventral thalamus and cortex. Low voltage, T -type calcium ( Ca
2+)-channels in the inferior olive 
and thalamus may play a role in the pathogenesis and treatment of ET. The T -type Ca2+-channel 
family is comprised of 3 different isoforms: Ca V3.1, CaV3.2, and Ca V3.3. These channels are 
involved in generation of physiological and pathophysiological rhythms in the brain. In the harmaline rodent model of ET, synchronous neuronal dis charges which are associated with T -
type Ca
2+-channels are increased. The abnormal discharges were attenuated in mice lacking the 
gene that encodes for Ca V3.1, and in wildtype mice, selective knockdown of Ca V3.1 in the 
inferior olive by shRNA suppressed the harmaline- induced tremor. The non- selective Ca2+ 
channel blocker ethosuximide was found to suppress tremor in the harmaline model and in a 
genetic model of ET, in a dose -dependent fashion.  
Praxis Precision Medicines Protocol PRAX-944 -221, Version 6.0 
PRAX -944 is an orally active, small molecule that belongs to the class of T-type Ca2+ -channe l 
blockers. PRAX-944 blocks all 3 T-type Ca2+ -channel subtypes with high potency and is 
therefore being studied for the treatment of ET. Different fo1mulations of PRAX-944 have been 
studied in 4 single and multip le ascending dose trials in healthy volunteers . The modified-release 
(MR)7 fo1mulatio n (80% of drug product released within 7 hours) , which will be used in this 
trial, was well tolerated at doses of up to 120 mg per day when admin istered in a titratio n 
regunen. 
In a human electroencep halogram (EEG) /polysomnograp hy clinical trial, PRAX -944 s howed 
robust suppres sion of the sigma frequency band during non-rapid eye movement (NREM) sleep , 
a marke r of sleep spind le activity, at the 20 mg, 40 mg, and 60 mg dose levels . Sleep spindles are 
prom inent oscillations of 11 to 15 Hz observed in the human scalp EEG during NREM sleep that 
are mediated by activatio n of T-type Ca2+ channels in the thalamus . Thus, these data suggest that 
PRAX -944 blocks T-type Ca2+ channe ls in the central nervou s syste m (CNS) at well tolerated 
doses. 
The aim of this development program is to evaluate whether oral administratio n of PRAX -944 
can provide therapeutic benefit to patients with ET. The study is divided into 2 parts: Pait A is 
designed to study the dose titration from 20 to 40 mg eve1 y morning (QAM) (ie, 2 weeks with 7 
days at each dose level) and Pait B is designed to study the dose titrat ion from 20 to up to 
120 mg QAM with at least 14 days of dosing at the highest tolerated dose for each pa1tic ipant. 
OBJEC TIVES AND END POINTS 
Part A 
Objective Endpoint 
Primruy 
• To evalua te the efficacy of PRAX-944 on • Change from Baseline to Day 7 and Day 14 
upper limb tremor in pa1ticipants with ET in The Essent ial Tr emor Rating Assessment 
Scale (TETRAS ) upper limb score (bilateral 
sum of items 4a, 4b, and 4c) 
Seconda1y 
• To evalua te the efficacy of PRAX-944 on • Change from Baseline to Day 7 and Day 14 
other measures of tremor severity in in: 
pruticipants with ET 0 TETRAS Pe1fo1mance subscale total 
score 
0 Acce lerometer-based upper limb score 
(bilateral sum of items 4a, 4b, and 4c) 
0 TETRAS Pe1fo1mance subscale 
indiv idual item scores 
• To evalua te the safety and tolerab ility of • Incidence and seve1ity of adverse events 
PRAX-944 in pa1ticipants with ET (AEs) 
• Changes in vital sign measurement s 
• Changes in clinical laborato1y results 
Confiden tial Page 15 of 84 
Praxis Precision Medicines 
Objective 
Explorato1y 
Confident ial Protocol PRAX-944 -221, Version 6.0 
Endpoint 
• Changes in electrocardiogram (ECG ) 
parame ters 
• Incidence of Columbia -Suicide Sevedty 
Rating Scale (C-SSRS) measured suicidal 
ideation or behavior 
Page 16 of 84 
Praxis Precision Medicine s 
Part B 
Objective 
Primruy 
• To evalua te the safety and tolerab ility of 
PRAX-944 in pa1t icipants with ET 
Seconda1y 
• To evaluate the efficac y of PRAX-944 on 
upper limb tremor in pa1t icipants with ET 
• To evaluate the efficac y of PRAX-944 on 
other measures of tremor severity in 
pruticipant s with ET 
• To evaluate the efficac y of PRAX-944 on 
measures of disease impact in prutic ipants 
with ET 
Explora to1y 
Confiden tial Protocol PRAX-944 -221, Version 6.0 
Endpoint 
• Incidence and seve1i ty of AEs 
• Change s in vital sign measurement s 
• Change s in clinic al laborato1 y results 
• Change s in ECG pru·ameter s 
• Incidence of C-SSRS measured suicidal 
ideation or behavior 
• Change from Baseline to Day 42 in TETRAS 
Upper Limb score (bilateral sum of items 4a, 
4b, and 4c) 
• Change from Baseline to Day 7 and Day 21 
in TETRAS Upper Limb score (bila teral sum 
of items 4a, 4b, and 4c) 
• Change from Baseline to Day 7, D ay 21, and 
Day 42 in the following: 
o TETRAS Pe1fo1mance subscale total 
score 
o Acce lerometer-ba sed upper limb score 
(bila teral sum of items 4a, 4b, and 4c) 
o TETRAS Pe1fo1mance individual item 
scores 
• Change from Baseline to Day 7, D ay 21, and 
Day 42 in the following: 
o TETRAS ADL subscale score 
o Quali ty of Life in Essential Tremor 
Questionnaire (QUEST) total and 
subscale s cores 
Page 17 of 84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 18 of 84 Objective Endpoint  
OVERALL DESIGN  
This multi- center clinical trial will assess the efficacy, safety, tolerability, and PK of PRAX -944 
in participants aged 18 years of age or older  who have had signs and symptoms consistent with 
ET for at least 3 years, with an onset before age 65.  
The clin ical trial will be conducted in 2 parts (Part A and Part B). Both parts will consist of 
3 periods: Screening/Baseline, Intervention, and Safety Follow -up. 

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 19 of 84 Part A of the clinical trial is open -label and will assess the safety and tolerability of PRAX -944, 
as well as the overall magnitude and pattern of change in ET severity. Daily dose levels will be 
titrated from 20 mg to 40 mg.  
Part B of the clinical trial consists of both an open -label titration phase and a randomized, 
double- blind, placebo- controlled wit hdrawal phase. Part B will assess the safety and tolerability 
of PRAX -944, as well as the overall magnitude and pattern of change in ET severity and the 
duration of that effect. Daily dose levels will be titrated from 20 mg to up to 120 mg during the 
open- label phase. In the randomized, double -blind, placebo- controlled withdrawal phase, 
participants will either be maintained on their final  open- label dose or switched to placebo.  
Participants who received study drug in Part A are not eligible for Part B (see  Exclusion 
Criterion #19).  
Screening/Baseline Period  
The Screening period for Part A and Part B will be up to 28 days (Day - 28 to Day - 1). Fourteen 
additional days (ie, 42 days total) will be allowed in the Screening period for participants who 
are discontinuing primidone.  
Prior to any procedures, participants will provide written informed consent to participate in the 
clinical trial. Key Scr
eening assessments will include medical history, demographics, physical 
examination, drug screen, clinical lab oratory evaluations and serum pregnancy for women of 
childbearing potential, 12- lead ECG, vital signs, C -SSRS, assessment of ET severity using the 
TETRAS Performa
nce subscale (including a video for independent review of eligibility), and a 
review of concom itant medications. To be eligible, potential participants who are taking 
prohibited medications
 will need to successfully discontinue these medications for at least 5 half -
lives or 14 days prior (whichever is the longer period of time) before the first dose of study drug.  
For those participants
 requiring the 14 additional days in the Screening period to discontinue 
primidone, all or some of the Screening assessments may need to be repeated, pending approval 
by the Sponsor’s M edical Monitor. 
For participants  in Part A , following confirmation of eligibility, including review by the Sponsor 
or designee, participants will complete Baseline assessments (Day 0). Day 0 (Baseline) activities 
may be combined with Day 1 activities, provided that Baseline activities ar e completed before 
dosing and that dosing occurs in the morning of Day 1. In addition, Baseline efficacy assessments should either be conducted on Day 0 or Day 1 pre -dose, but not both to avoid 
learning effects.  
For participants in Part B , TETRAS Upper Li
 mb items will also be completed with 
accelerometry at Screening and via telehealth on Day - 2 of the Screening period. The Screening 
telehealth visit i
s needed to ensure participants can complete the TETRAS Upper Limb  
assessment successfully via telehealth and to provide a pre -dose measure. Additional 
assess
ment
s added to Part B screening include TETRAS ADL and . Following 
confirmation of eligibi
lity, including review by the Sponsor or designee, participants will 
complete Baseline assessments (Day 1). Some Baseline assessments (as indicated in Table 3) 
may be completed on D
ay -1. 
 -
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 20 of 84 Intervention Period  
Part A 
On Day 1, participants will receive a 20 mg dose of PRAX -944, administered in the morning. 
Participants will remain in a clinical setting under medical observation for approximately 
6 hours. TETRAS Performance assessments will be performed before dosing and 6 hours post -
dose. After the first dose, participants will continue QAM dosing at home after breakfast through 
Day 7. Participants will return to the clinic on Day 7 for efficacy testing at the 20 mg dose level. 
On Day 8, the dose will increase to 40 mg QAM after breakfast through Day  14 for efficacy 
testing at the 40 mg dose level. Participants will return to the clinic on Day 14 for efficacy 
testing at the 40 mg dose level. Participants who agree to optional additional PK sampling will 
remain overnight in the clinic on Day 1, Day 7, and Day 14.  
Key safety measures will include clinical laboratory evaluations, 12 -lead ECG, C -SSRS, and 
vital signs ( Table 2 ). Key efficacy assessments will include the TETRAS Performance subscale, 
(Table  2). Blood s amples will be 
obtained for the determination of PRAX -944 plasma concentrations using a validated 
bioanalytical method and may also be used for exploratory method development and/or metabolite characterization.  
Part B  
Open -label Titration Phase  
On Day 1, participants will receive a 20 mg dose of PRAX -944 on an empty stomach ( at least 1 
hour before  breakfast). Participants will remain in a clinical setting under medical observation 
for approximately 6 hours. TETRAS Performance assessments will be performed before dosing 
and 6 hours (±2) post -dose. 
For dosing on Day 2 through Day 41, participants will be instructed to dose QAM at least 1 hour before breakfast  at home . 
Participants will continue taking PRAX -944 20 mg QAM at home through Day 3.  
On Day 3, participants will receive a telephone call from site staff to inquire about AEs  and 
concomitant medications, confirm dose escalation, and remind the participant about the number 
of study drug tablets to take on Day 4 through Day 7.  
On Day 4, participants will escalate to 40 mg QAM through Day 7, when they will return to the clinic for safety assessments and efficacy testing. On Day 8, participants should escalate to 60 mg QAM through Day 14.  
On Day 14, participants will receive a telephone call from site staff to inquire about AEs  and 
concomitant medications, confirm dose escalation, and remind the participant about the number of study drug tablets to take on Day 15 through Day 21.  
On Day 15, participants should escalate to 80 mg QAM through Day 21, when they will return to the clinic for safety assessments and efficacy testing. On Day 22, participants should escalate to 100 mg QAM through Day 28.  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 21 of 84 On Day 28, participants will receive a telephone call from site staff to inquire about AEs  and 
concomitant medications, confirm dose escalation, and remind the participant about the number 
of study drug tablets to  take on Day 29 through Day 42.  
On Day 29, participants will escalate to 120 mg QAM through D ay 42, when they will return to 
the clinic for safety assessments and efficacy testing.  The dose on Day 42 will be taken in the 
clinic (see Double- blind Randomized Withdrawal Phase below). 
On Day 35, participants will receive a telephone call from site staff to inquire about AEs  and 
concomitant medications.  
On Day 41, participants will complete a TETRAS Performance Upper Limb assessment via a 
telehealth visit.  
If at any point during the open -label titration phase a participant does not tolerate escalation and 
the Investigator returns the participant to a lower dose  level, the participant will continue 
according to the schedule outlined above, but no further dose changes will be allowed. The 
Investigator should discuss the decision to continue at a lower dose level with the Sponsor and 
Medical Monitor. Participants can only change to a lower dose level once, and no dose changes may occur after Day 36.  
Double -blind Randomized Withdrawal Phase  
On Day 42, participants will complete the final clinic visit of the open -label titration phase. 
Participants will receive their dose of PRAX -944 in the clinic on an empty stomach ( at least 1 
hour before  breakfast). Participants will  remain in a clinical setting under medical observation 
for approximately 6 hours. TETRAS Performance assessments will be performed before dosing and 6 hours (±2) post -dose. 
After Day 42, participants will either continue receiving PRAX -944 at their current dose or 
switch to placebo, depending on their randomization. Randomization in a 1:1 fashion may be completed at any time on Day 37 through  42. 
Safety Follow -up Period  
Part A  
The Safety Follow -up period will take place from Day 15 to Day 21. At the end of the Safety 
Follow- up period, participants will return to the clinic on Day 21 (±1 day) for the final clinical 
trial assessments ( Table 2).  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 22 of 84 Part B  
The Safety Follow -up period will take place from Day 57 to Day 70. At the end of the Safety 
Follow- up period, participants will return to the clinic on Day 70 for the final clinical tr ial 
assessments ( Table 3). 
Safety Monitoring  
The Sponsor will review ongoing safety data. The clinical trial may be stopped, or clinical trial 
enrollment suspended if:  
• The Sponsor, in consultation with the Principal Investigators, consider that the number and/or severity of AEs justify discontinuation of the clinical trial  
• The Sponsor makes a decision to do so 
Critical safety endpoints are listed in Section 8.2 . AEs and concomitant medication and 
procedures use will be monitored from the time of informed consent to Day 21 (±1 day) in Part 
A and to Day 70 in Part B. At that time, participants will have completed the clinical trial.  
Renal function monitoring will be based on the KDIGO criteria  for acute kidney injury (AKI) as 
outlined in Section 8.2.4.1 . If a participant’s  laboratory values exceed these thresholds, dosing of 
that participant will be stopped, and the  laboratory tests repeated.  
NUMBER OF PART ICIPANTS  
Part A  
Up to 12 participants are planned to be administered PRAX -944. 
Part B  
Approximately 12 participants are planned to be administered PRAX -944 for the first 42 days 
followed by randomization (1:1) to 2 additional weeks on the highest tolerated  dose of PRAX -
944 or placebo.  Up to 12 additional participants may be enrolled at the discretion of the Sponsor 
to ensure inclusion of a broad range of tremor severity.  
Participant Replacement  
Participants who withdraw from either Part A or Part B prior to completion of the clinical trial 
may be replaced at the discretion of the Sponsor. No more than 6 participants in either part of the 
study will be replaced.  
DURATION OF CLINICAL TRIAL  
Participants will be part of the clinical trial for the following time intervals:  
Part A  
Screening/Baseline Period  Up to 28 days (+14 days if on primidone)  
Intervention Period  14 days  
Safety Follow -up Period 7 days  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 23 of 84 Total Participation  Up to 49 days (63 days if on primidone)  
Part B  
Screening/Baseline Period  Up to 28 days (+14 days if on primidone)  
Safety Follow -up Period 14 days  
Total Participation  Up to 98 days (112 days if on primidone)  
INCLUSION/EXCLUSION CRITERIA  
Inclusion Criteria  
A participant mu st meet the following criteria at Screening and Baseline (unless otherwise 
specified) to be eligible to participate in this clinical trial:  
I 1. Male or non- pregnant, non- lactating female aged 18 years or older . 
I 2. Willing and able to understand and sign an informed consent document indicating 
that he/she understands the clinical trial purpose, the clinical trial procedures, and that 
he/she is willing to participate in the clinical trial and comply with the protocol.  
I 3. Body mass index (BMI) at Screening between 18 and 40  kg/m2, inclusive.  
I 4. Clinical diagnosis of ET consistent with Movement Disorders Society Criteria, a duration of ET of at least 3 years and with onset before the age of 65.  
I 5. Moderate to severe ET as defined by the following:  
a. A combined bilateral score of ≥10 on the TETRAS Upper Limb  items 4 a, b, c. 
(UL tremor  severity at Screening will be confirmed by central video review, for 
eligibility ) 
OR 
b. A score of ≥ 2 on 2 or more of the following TETRAS activities of daily living 
(ADL) subscale items: (2) Feeding with a spoon, (3) Drinking from a glass, (5) Dressing, (6) Pouring, (9) Writing  
OR 
c. A score of ≥ 2 on 1 of the following TET RAS ADL subscale items: (2) Feeding 
with a spoon, (3) Drinking from a glass, (5)  Dressing, (6) Pouring, or (9) Writing  
AND a score of ≥ 2 on both of the following TETRAS ADL subscale items: 
(10) Working and (12) Social Impact  
Note:  ET severity at Baseline will be confirmed by the Investigator at the clinical trial site.  
I 6. Those currently receiving any medication for their ET must be willing and able to 
discontinue all but 1 tremor medication and be on a stable dose for at least 28 days.  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 24 of 84 I 7. Willing to comply with medically acceptable method of contraception as defined in 
Section 5.4.3 . 
Exclusion Criteria  
A participant who meets any of the following criteria at Screening or Baseline (unless otherwise specified) will be excluded from this clinical trial:  
E 1. Known hypersensitivity to any component of the formulation of PRAX -944. 
E 2. Unwilling or unable to refrain from episodic use of medication(s)/substance(s) that 
might interfere with the evaluation of tremor during the trial. Stable use of 
medication(s)/substance(s) that might impact tremor, including beta -agonist 
bronchodilators, is allowed so long as the tremor is judged by the investigator to be primarily due to the participant's ET diagnosis.  
E 3. Trauma to the nervous system within 3 months preceding the onset of tremor.  
E 4. Clinical evidence of psychogenic tremor as ascertained by the Investigator.  
E 5. History of other medical, neurological or psychiatric condition that may explain or cause tremor, including but not limited to Parkinson's disease, dystonia, cerebellar 
disease, family history of Fragile X syndrome, traumatic brain injury, alcohol abuse or withdrawal, benzodiazepine abuse or withdrawal, multiple sclerosis, 
polyneuropathy, and endocrine states such as hyperthyroidism.  
E 6. Prior magnetic reso nance- guided focused ultrasound or surgical intervention for ET 
such as deep brain stimulation or thalamotomy.  
E 7. Botulinum toxin injection for ET in the 6 months prior to Screening.  
E 8. Unwilling or unable to discontinue primidone.  
E 9. Unwilling or unable to refrain  from alcohol 24 hours before and during clinical trial 
visits. Or regular use of alcohol that would preclude abstinence from alcohol in this 
period, in the judgement of the Investigator.  
E 10.  Substance use disorder in the judgement of the Investigator 
E 11.  Sporadic use of a benzodiazepine, sleep medication or anxiolytic, that in the 
judgement of the Investigator or Sponsor would confound the assessment of tremor. Stable use at a consistent dose not exceeding the equivalent of 2 mg/day of lorazepam 
(see Section 6.5.2 ) is allowed as long as tremor persists against the background of 
regular medication use.  
E 12.  Use of prescription or non- prescript ion products and food known to be strong 
inhibitors or inducers of CYP3A4 or known to be a P -gp substrate (see Section 6.5.1 ) 
which cannot be discontinued at least 5 half -lives or 14 days prior (whichever is the 
longer period of time) to Baseline and withheld throughout the clinical trial, including 
primidone. 
E 13.  The participant has any of the following at the Screening visit: a serum total bilirubin 
value >1.5×ULN; a serum alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) value >2×ULN. As an exception, participants that present 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 25 of 84 with elevated bilirubin in the absence of elevations in ALT or AST that fits the 
pattern of Gilbert’s syndrome may be enrolled after discussion with the m edical 
monitor if their conjugated bilirubin is within the ULN.  
E 14.  Criterion r emoved from protocol  in Version 5.0 . 
E 15.  History of any suicide attempt within the past 2 years.  
E 16.  History of structural heart disease (eg, congestive heart failure, depressed ejection fraction or left ventricular hypertrophy) or clinically significant cardiac arrhythmias 
(eg ventricular tachycardia) excluding sinus arrhythmia.  
E 17.  History of cancer treated with chemotherapy  
E 18.  Any other significant disease, disorder,  laboratory abnormalities, or environmental 
factor that, in the opinion of the Investigator or Sponsor, may either put the participant at risk due to participation in the clinical trial, may influence or confound 
the result of  the clinical trial, or affect the participant’s ability to participate in the 
clinical trial.  
E 19.  Has previously received treatment with PRAX -944 in any clinical trial (including 
Part A of the current trial for participants enrolling in Part B)  
TEST PRODUCT, REFERENCE THERAPY, AND ADMINISTRATION  
20 mg PRAX -944 MR7 tablets or matching placebo will be administered orally and provided in 
pre-packaged containers to the participants.  
DOSE/ROUTE/REGIMEN  
Part A  
All participants will receive PRAX -944 orally, 20 mg QAM  for 7 days and 40 mg QAM for 7 
days. 
Part B  
Open -label Titration  
The planned titration schedule for  PRAX -944 is as follows : 
• 20 mg QAM for 3 days  
• 40 mg QAM for 4 days  
• 60 mg QAM for 7 days  
• 80 mg QAM for 7 days  
• 100 mg QAM for 7 days  
• 120 mg QAM for 14 days  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 26 of 84 SAMPLE SIZE  
The samp
le size of each part (up to 12 participants) is a convenience sample. The sample size 
was not selected according to any statistical power calculation. Instead, the sample size was 
determined according to feasibility and is thought to provide sufficient efficacy and safety data to 
inform the  development of future controlled studies with PRAX -944 in participants with ET. 
Part B sample size may be increased to up to 24 participants  to ensure inclusion of a broad range 
of tremor severity. In the open- label phases of the trial (Part A and Part B,  open -label titration), a 
sample size of at least 10 participants would provide an 80% probability of observing at least 1 
AE with an underlying incidence of 15% or greater. In addition, 10 participants should also provide approximately 80% power to detect  an effect size of 1.0 on the primary endpoint of 
change from Baseline in TETRAS Upper Limb  score.  
STATISTICAL METHODS  
For all data displays, separate summaries will be generated for each part of the clinical trial. For 
the randomized portion of Part B, data will be summarized by the randomized continuation 
treatment. Safety, tolerability, PK, and efficacy variables will be summarized using descriptive statistics. Descriptive summaries for categorical variables will include counts and percentage. 
Descript ive summaries for continuous variables will include number of participants (n), mean, 
standard deviation (SD), median, minimum, and maximum. Where appropriate, 95% confidence intervals (CIs) may be reported. Summaries will be presented by time point, where  appropriate.  
Unless specified otherwise, all data recorded will be listed by participant.  
Reported values and change from baseline values in TETRAS Upper Limb  score, TETRAS 
Per
formance subscale total and individual score s,
The Enrolled Anal
ysi
s set includes all participants who sign an informed consent form and are 
provided with an enrollment number. The Enrolled Analysis set will be used for all participant disposition analyses.  
The Safety Analysis set includes all participants who received at least 1 dose of study drug. Participants will be classified according to actual intervention received. The Safety Analysis set 
will be used for all demographic, baseline characteristics, prior/concomitant medication, study 
drug exposure, and safety analyses.  
The Full Analysis set includes all participants who took at least 1 dose of study drug and have a 
valid Baseline TETRAS assessment and at least 1 valid post -Baseline TETRAS assessment. The 
Full Analysis set will be used for the analysis of all efficacy data.  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 27 of 84 The PK Analysis S et includes all participants who received at least 1 dose of study drug and 
have at least 1 evaluable plasma concentration. The PK Analysis S et will be used for the analysis 
of plasma concentrations and PK parameters.  
Adverse event data will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). The number and percentage of participants experiencing any treatment -emergent 
AE (TEAE) will be summarized by system organ class (SOC) and preferred term (PT). In addition, TEAEs will be summarized similarly by maximum severity and maximum relationship to PRAX -944. Serious AE s (SAEs) and TEAEs leading to discontinuation of PRAX -944 will be 
listed. Reported values and change from Baseline values in vital signs, ECG parameters, and 
hematology and clinical chemistry laboratory parameters will be summarized by time po int. 
For the C -SSRS, the number and percentage of  participants with suicidal ideation or behavior 
events will be tabulated.  
For Part A, standard PK parameters will be estimated using noncompartmental methods based on 
the concentration -time data. These parameters will include, where possible, C
max, Tmax, t1/2, 
AUC 0-tau, CL/F and Vd/F. Part B, concentration -time data will be su mmarized. Exploratory 
analyses examining the relationship between PK and efficacy parameters may be performed for 
the PK Analysis S et. 
Praxis Preci sion Medicine s Protocol PRAX-944-22 1, Version 6.0 
1.2. Study Schema 
Figure 1: Study Schema 
Part A (N=12): Open-label Study of 20 mg and 40 mg 
Day-28 to •1 
Screening DayO 
Baseline Day 1 
20 mgQ AM 
study drug Day 7 
Last day of 
20mg 
QAM Daya 
40 mg 
QAM study 
drug Day 14 
Last day of 
40mgOAM 
Part B (N=12): Open-label Titration and 
Randomized Withdrawal Study of 120 mg Day 15 to 21 
Safety 
Follow-up 
Period 
1 :1 Day -28 to -1 Day 1-3 Day4•7 Day 8·14 Day 15-21 Day 22-28 Day 29-42 Randomization 
Screeni ng PRAX-944 PRAX-944 PRAX-944 
40mg QAM 60 mgQAM 80mgQAM 
a1.1i1c 
Vh"4 
Oay21 PRAX •944 PRAX· 944 
100mgQAM 120mgQAM 
Ooy2S 
= Site conducted telehEellh al 
home TETRAS uppe , limb 
items assessment 
= Telephone checi\•i n 
Note: This sche ma is intended to provide a visual reference to the basic study design . Key aspects of 
the study, including flexibility with dose level and visit schedule are not represented here -please refer to 
the text of the protocol and the SoA for these details. 
Confiden tial Page 28 of84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 29 of 84 1.3. Schedule of Activities  
The schedule of clinical trial activities for Part A is presented in Table 2. The schedule of clinical 
trial activities for Part B is presented in Table 3.
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 30 of 84 Table  2:  Schedule of Activities (SoA) – Part A  
Visit Days  Day - 28 to 
Day -1 
(Screening)  Day 0* 
(Baseline)  Day 1  Day 7 (±1)  Day 14 (±1)  Day 21 (±1) 
End of 
Clinical 
Trial  or 
Early 
Termination  
CLINICAL TRIAL ENTRY AND GENERAL ASSESSMENTS  
Informed Consent  X      
Inclusion/ Exclusion  X X     
Demographic Data X      
Medical History  X      
Body Weight/ Height  X      
Drug/ Alcohol Screen a X X     
Pregnancy test  X (serum)  X (urine)     X (urine)  
SAFETY ASSESSMENTS  
Vital Signs b X X X X X X 
Physical Examination  X X      X  
Clinical Laboratory Tests c X X  X X X 
12-lead ECG d X X  X X  
C-SSRS (Baseline/Screening)  X      
C-SSRS (Since Last Visit)   X  X X X 
AE Monitoring  X 
Concomitant Meds/ Procedures  X 
EFFICACY ASSESSMENTS  
TETRAS Performance e X X X X X X 
Praxis Precision Medicines 
Visit Days 
TETRAS Video Recording r 
TETRAS Pe1fo1mance Upper Limb Items wi th 
Acce lerometer g 
--
Blood Collect ion for Study Dmg Concentrat ion 
(sparse sampling) h 
Blood Collect ion for Study Dmg Concentrat ion 
(sedal sampling) i Day-28 to Day0* Day-1 (Baseline) Day 1 
(Scree ning ) 
X X X 
X X 
PHARMA COKINETICS 
X 
0 
STUDY DRUG Protocol PRAX-944 -221, Version 6.0 
Day 21 ( ±1) 
End of 
Clinical Day7 (±1) Day 14 (±1) Trial or 
Early 
Termination 
X X X 
X X X 
I I 
I I 
X X 
0 0 
X 
AE=adverse event; C-SSRS =Colwnbia-Suicide Severity 
Rating Scale; ECG=e ectrocar rogram ; O=ophona ; ; TETRAS =T e Essential Tremor Rating Assessmen t Scale . 
* Day O (Baseline) activities may be combined with Day 1 activities , provided that Baseli ne activities are comp leted before dosing in the moming. Base line 
testing of TETRAS Performance , TETRAS Video Recordi ng, and TETRAS Performa nce Upper Limb Items with Accelerometer should all be done on the 
same day and can occw- on Day O or Day 1 pre-dose, but not both . 
• Urine sample for assessment of selected drug s and a breath sample for alcohol screen . 
b Vital signs (pulse rate, respirato ry rate, temperatw-e , and blood pressw-e [ after the partic ipant has been supine for at least 5 minu tes and standing for at least 2 
minutes]) . On Day 1, should be performed 2 and 6 how-s after dosing (±30 min) . 
c Includi ng CBC , clinical chemi stry, coagulatio n factors , viral serology screen, exploratory mine biomarker s, w-inalysis and w-ine albumin . Coagulation factors 
and viral serology screen collected at Screening only . 
d Tripl icate measmemen t will be taken at Screening only; for all other timepoin ts, single measw-emen t is acceptable . 
e Screening, Day O and Day 21: completed anytime; Day 1, pre-dose (if not done on Day 0) and 6 (±2) how-s post-dose; Day 7 and Day 14, 6 (±2) how-s post-
dose . 
Confident ial Page 31 of84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 32 of 84 Visit Days  Day - 28 to 
Day -1 
(Screening)  Day 0* 
(Baseline)  Day 1  Day 7 (±1)  Day 14 (±1)  Day 21 (±1) 
End of 
Clinical 
Trial  or 
Early 
Termination  
f The TETRAS Performance assessment will be captured on video for central reading. The local rater will rate the same TETRAS Pe rformance assessment that 
is captured on video. The Screening video will be independently assessed for el igibility.  
g To be performed 2 consecutive times separated by at least 30  minutes, the first of the two accelerometer assessments should be completed immediately after 
the TETRAS Performance assessment. All 3 maneuvers in the upper limb item (sub-items 4a, 4b, and 4c) will be completed for both arms, first for the 
RIGHT arm and then for the LEFT.  
h Day 1: 0 (pre -dose); Day 1, 7 and 14; post -dose immediately after completion of the 2nd accelerometer -based upper limb assessment; When PK sampling 
timepoints coincide with  the TETRAS Performance timepoints or accelerometer -based assessment timepoints the PK sample is to be obtained last.  
i Optional samples collected at sites that have capabilities to perform serial sample collection: Day 1, 7 and 14: 0 (pre -dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 
hours post -dose. All collection times up to 4 hours post -dose have a ±15 min window and a ±30 min window thereafter. 24-hour timepoint samples are to be 
taken prior to the AM dose. When PK sampling timepoints coincide with the TET RAS Performance timepoints or accelerometer- based assessment 
timepoints the PK sample is to be obtained last.  
j Administered in clinic on Day 1. All other days it should be taken in the morning, within 30 minutes after breakfast. On Day 1 participant should be observed 
in clinic for approximately 6 hours before discharge. Study drug is dispensed (20 mg QAM for Day 1 to Day 7; 40 mg QAM for Day 8 to Day 14).  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 33 of 84 Table 3:  Schedule of Activities (SoA) – Part B  
Study Phase  Screening   
Open -label Titration  
Visit Days  
(Visit Window)  Day - 28 to  
Day -1 
Day 1 
(Baseline)  Day 
3 Day 
7 Day 
14  Day 
21 Day 
28 Day 
35 Day 
41 Day 
42 
 Day 
-2 
(-2) 
CLINICAL TRIAL ENTRY AND GENERAL ASSESSMENTS  
Informed Consent  X           
Inclusion/Exclusion X  X*         
Demographic Data X           
Medical History  X           
Body Weight/Height  X           
Drug/Alcohol Screen a X  X*         
Pregnancy test  X 
(serum)   X (urine)*         
SAFETY ASSESSMENTS  
Vital Signs b X  X  X  X    X 
Physical Examination  X  X*         
Clinical Laboratory 
Tests c X  X*  X  X    X 
12-lead ECG d X  X*  X  X    X 

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 34 of 84 Study Phase  Screening   
Open -label Titration  
Visit Days  
(Visit Window)  Day - 28 to  
Day -1 
Day 1 
(Baseline)  Day 
3 Day 
7 Day 
14  Day 
21 Day 
28 Day 
35 Day 
41 Day 
42 
 Day 
-2 
(-2) 
C-SSRS 
(Baseline/Screening)  X           
C-SSRS (Since Last 
Visit)    X*  X  X    X 
Phone Call Check -in    X  X  X X   
AE Monitoring  X 
Concomitant Meds/ 
Procedures  X 
EFFICACY ASSESMENTS  
TETRAS Performance e X  X  X  X    X 
TETRAS Video  
Recording f X  X  X  X    X 
TETRAS Performance Upper Limb Items with Accelerometer 
g X  
X  X  X    X 
Telehealth TETRAS Upper Limb Items Assessment   X        
X  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 35 of 84 Study Phase  Screening   
Open -label Titration  
Visit Days  
(Visit Window)  Day - 28 to  
Day -1 
Day 1 
(Baseline)  Day 
3 Day 
7 Day 
14  Day 
21 Day 
28 Day 
35 Day 
41 Day 
42 
 Day 
-2 
(-2) 
TETRAS ADLh X  X  X  X    X 
              
              
              
QUEST    X  X  X    X 
              
              
PHARMACOKINETICS  
Blood Collection for 
Study Drug Concentration 
i   
X  X  X    X 
STUDY DRUG  
Randomization j           X 
Study Drug Dispensing    X  X  X    X 
Study Drug Administration 
k   X 
(open label)  
-I I I I I -I I I -I I I -I I I I I I • I I I I I I 
Prax is Precision Medicine s Protocol PRAX-944 -221, Version 6.0 
Study Phase 
Visit Days 
(Visit Window) Scree ning 
Day-28 to 
Day-1 
Day 1 
(Base line) Day 
3 Day 
7 Open-lab el Titration 
Day 
14 Day 
21 Day 
28 Day 
35 Day 
41 
CBC=complete blood count ; 
-SSRS=Columbia-Suic ide Severity Rating Scale; 
ECG=elec trocardiogram ; Meds=Medica tions; ; PK=phannacokinetic s; QAM =every moming ; QUE ST=Quali ty 
of Life in Essential Tremor Questionnaire ; TETRA S=The Essential Tremo r Rating Assessment Scale. 
* May be perfoimed on Day -1. 
• Urine sa mple for assessment of selecte d drng s and a breath sample for alcohol screen . 
b Vital signs include pulse ra te, respiratory rate, temperature , and blood pressure. Blood pressure must be measured once after the participant has been supine 
for at least 5 minute s and once after the paiticipant has been standing for at least 2 minu tes. On Day 1, vit al signs should be measured pre-do se, 2 hour s post-
dose (± 30 min), and 6 hours post-dose (±30 min). 
c Including CBC , clinical chemistt y , coagul ation factors, viral serology screen, urinal ysis, and urine albumin . Coagul ation factors and viral serology screen 
collected at Screening only. 
d A triplica te measurement must be taken at Screening only; for all other timepoint s, a single measurement is acceptable. 
e TETRA S can be comple ted anytime at Screening and Day 70. On other days, the follo wing timing should be follo wed: 
Day 1: pre-dose and 6 (±2) hour s after a 20 mg QAM dose 
Day 7: 6 (±2) hours after a 40 mg QAM dose 
Day 21: 6 (±2) hour s after an 80 mg (or highe st tolera ted dose) QAM dose 
Day 42: pre-dose and 6 (±2) hours after a 120 mg (or highest tolera ted dose) QAM dose 
Day 56: 6 (±2) hour s post-dose 
f The TETRA S Performan ce assessment will be ca ptured on video for central reading . The local rater must rate the same TETRA S Perfonnance assessment as 
that which is captured on video for central reading . The Screening video will also be independentl y assessed for eligibility. 
g Kine sia ONE assessment s must be completed immedia tely after the TETRAS Perfoimance assessment s (including both pre-dose and post-dose assessment s 
on Day 1 and Day 42). After each TETRA S Perfoimance assessment , Kine sia ONE assessment s should be completed twice separate d by at least 30 minutes. 
All 3 ma neuvers in the upper limb item (sub-items 4a, 4b, and 4c) will be completed for both aims , first for the RIGHT aim and then for the LEFT . 
h For visits with multiple TETRAS assessment s, the TETRAS ADL subscale should only be assessed once . On Day 1, t he ADL subscale should be completed 
pre-dose . On day 42, the ADL subscale should be comple ted 6 (±2) hours after the QAM dose. 
i On Day 1 and Day 42 blood sample s should be collec ted at the follo wing timepoint s: pre-dose and 0.5, 1, 2, 4, a nd 6 hours post-dose. The 6-hour post-dose 
sample will be collec ted immedia tely after comple tion of the second Kine sia ONE assessment . When PK sampling timepoint s coinci de w ith the TETRAS 
Confiden tial Page 36 of84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 37 of 84 Study Phase  Screening   
Open -label Titration  Double -Blind 
Randomized 
Withdrawal Safety 
Follow-
up 
Visit Days  
(Visit Window)  Day - 28 to  
Day -1 
Day 1 
(Baseline)  Day 
3 Day 
7 Day 
14  Day 
21 Day 
28 Day 
35 Day 
41 Day 
42 Day 56  Day 
70/ET 
(End of 
Clinical 
Trial)   Day 
-2 
(-2) 
Performance timepoints or accelerometer -based as sessment timepoints, the PK sample is to be obtained last. On Days 7, 21, and 56; samples should be 
collected 2 hours post -dose. Blood collection can be completed anytime on Day 70.  
j Participants will be randomized (1:1) to receive either placebo or PRAX -944 from Day 43 to Day 56. Randomization can occur on Day 37 through  Day 42.  
k On Day 1 and 42, study drug must be administered in the clinic on an empty stomach (at least 1 hour before  breakfast, which will be provided at the site) and 
the participant sho uld be observed in the clinic for approximately 6 hours before discharge. On all other days, participants should be instructed to take study 
drug at least 1 hour before  breakfast in the morning at home . The escalation schedule is as follows: 20 mg, Day 1 through Day 3; 40 mg, Day 4 through Day 
7; 60 mg, Day 8 through Day 14; 80 mg, Day 15 through Day 21; 100 mg, Day 22 through Day 28; and 120 mg, Day 29 through Day 42. Participants will 
receive blinded study drug on Days 43 to 56. During blinded treatment p eriod, participants should take the same number of tablets per day as taken during 
Days 36 to 42.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 38 of 84 2. INTRODUCTION  
2.1. Background and Clinical Trial Rationale  
Essential Tremor ( ET) is one of the most common neurological disorders with a prevalence of 
nearly 1% (Louis 2010) . It is characterized by a 6 to 12 Hz postural and kinetic tremor. Tremor 
typically occurs in the hands, arms, head, and voice, and is less common in the face, legs, and 
trunk. ET, by definition, is not associated with other neurological signs, although a resting tremor 
and impairments in balance, particularly tandem gait, have been described (Deuschl 2011) . The 
diagnosis of ET is based on medical history and neurological exam as described in The International Parkinson and Movement Disorders Society Consensus Statement on the Classification of Tremors (Bhatia 2018) . 
There is a range in the  severity of ET; some patients require no treatment, whereas others have 
severe disability with impairment in activities of daily living ( ADLs) suc h as dressing and eating. 
Treatments for ET include pharmacological therapies, regional injection of botulinum toxin 
(off-label usage), and surgical therapies for those with severe disability. The most effective 
pharmacological therapies are propranolol and primidone. They have limited efficacy, with about 50% of patients having a durable yet incomplete response. Dose -limiting side effects are 
common and include bradycardia for propranolol and sedation and dizziness for primidone 
(Deuschl 2011). Surgical therapies, including deep brain stimulation and ablation of the nucl eus 
ventralis intermedius of the thalamus, are effective but they are reserved for medically refractory 
patients due to the risks associated with brain surgery. Many patients who are eligible for 
surgical therapies do not elect to have these procedures (Elias 2016). Thus, there is a high unmet need for efficacious and well -tolerated pharmacological therapies for ET.  
While the genetics and pathophysiology of ET is not fully understood, it is thought to involve abnormal activity of cerebellar afferent an d efferent pathways. This network consists of input 
from the inferior olive to the cerebellar cortex, and outflow through deep cerebellar nuclei to the 
ventral thalamus and cortex (Park 2013). Low voltage, T -type calcium (Ca
2+)-channels in the 
inferior olive and thalamus may play a role in the pathogenesis and treatment of ET. The T -type 
Ca2+-channel family is comprised of 3 different isoforms: Ca V3.1, CaV3.2, and Ca V3.3. These 
channels are involved in generation of physiological  and pathophysiological rhythms in the 
brain. In the harmaline rodent model of ET, synchronous neuronal discharges which are associated with T -type Ca
2+-channels are increased. The abnormal discharges were attenuated in 
mice lacking the gene that encodes f or CaV3.1, and in wildtype mice, selective knockdown of 
CaV3.1 in the inferior olive by shRNA suppressed the harmaline -induced tremor (Park 2010) . 
The non- selective Ca2+-channel blocker ethosuximide was found to suppress tremor in the 
harmaline model and in a genetic model of ET, in a dose -depe ndent fashion (Handforth 2010) . 

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 39 of 84 In a human ( electroencephalogram ) EEG/p olysomnography clinical trial, PRAX -944 showed 
robust suppression of the sigma frequency band during non- rapid eye movement  (NREM) sleep, 
a marker of sleep spindle activity, at the 20  mg, 40 mg, and 60 mg dose levels. Sleep spindles are 
prominent oscillations of 11 to 15 Hz observed in the human scalp EEG during NREM sleep that 
are mediated by activation of T -type Ca2+-channels in the thalamus. Thus, these data suggest that 
PRAX -944 blocks T -type Ca2+-channels in the central nervo us system (CNS) at  well-tolerated 
doses.  
The aim of this development program is to evaluate whether oral administration of PRAX -944 
can provide therapeutic benefit to patients with ET. The study is divided into 2 parts: Part A is designed to study the dose  titration from 20 to 40 mg every morning ( QAM ) (ie, 2 weeks with 7 
days at each dose level) and Part B is designed to study the dose titration from 20 to up to 
120 mg QAM with at least 14 days of dosing at the highest tolerated dose for each participant.  
2.2. Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events (AEs) of PRAX-944 may be found in the Investigator’s Brochure (IB). 
2.3. Known Potential Benefits  
Since PRAX -944 has not yet been studied in the ET population, there are no known benefits.  
2.4. Known Potential Risks  
In the Z944-104 study, administration of 20 and 40 m g doses of P RAX -944 
on Day 1 of dosi ng was well tolerated, but a 60 mg si ngle dose led to nausea and vomiting. In 
a
ddition, a 20 mg daily dose and a 40 mg daily dose, ea ch administered for 8 days, were 
det
ermined to be safe and tolerable in healthy volunteers. More rec ently, i n the com pleted 
PRAX - 944- 105 study, dai ly doses up to 120 mg were determine d to be safe and  wel l t olerated in 
healthy volunteers fol lowing a titration schedule nearly identical to the schedule planned for thi s 
clinical trial. 
The more common (5 or mor e in 100) or me dically relevant AEs that have occurred with PRAX -
944 are as fol lows: feeling abnormal or dizzy, heada che, nausea, elevated mood, visual 
hallucinations, drowsiness, difficulty concentrating, skin tingling, fatigue, numbness, tremor, 
poor sleep, feeling anxious, spinning sensation, vomiting, and strange dreams (see IB Section 6 
for additional information). Most of these side effects were short-lived, a nd all s ymptoms 
resolved. 
No serious AEs (SA E)s have bee n reported with PRAX -944. 

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 40 of 84 

Praxis Precision Medicines Protocol PRAX-944 -221, Version 6.0 
3. OBJ ECTIVES AND ENDPOI NTS 
To evaluate the efficacy, safety, tolerabi lity, and phaimacok inetics (PK) of PRAX -944 in adults 
with ET. 
3.1. Part A 
Objective 
Primruy 
• To evalua te the efficacy of PRAX-944 on 
upper limb tremor in pa1ticipants with ET 
Seconda1y 
• To evalua te the efficacy of PRAX-944 on 
other measures of tremor severity in 
pruticipants with ET 
• To evalua te the safety and tolerab ility of 
PRAX-944 in pa1ticipants with ET 
Explora to1y 
Confiden tial Endpoint 
• Change from Baseline to Day 7 and Day 14 
in The Essent ial Tr emor Rating Assessment 
Scale (TETRAS ) upper limb score (bilateral 
sum of items 4a, 4b, and 4c) 
• Change from Baseline to Day 7 and Day 14 
in: 
o TETRAS Pe1fo1mance subscale total 
score 
o Acce lerometer-based upper limb score 
(bilateral sum of items 4a, 4b, and 4c) 
o TETRAS Pe1fo1mance subscale 
indiv idual item scores 
• Incidence and seve1 ity of adverse events 
(AEs) 
• Changes in vital sign measurement s 
• Changes in clinical laborato1 y results 
• Changes in electrocru·diogram (ECG) 
parameters 
• Incidence of Columbia-Suicide Sever ity 
Rating Scale (C-SSRS ) measured suicidal 
ideation or behavior 
Page 41 of 84 
Praxis Precision Medicine s Protocol PRAX-944 -221, Version 6.0 
3.2. Part B 
Objec tive Endpoint 
Primruy 
• To evalua te the safety and tolerab ility of • Incidence and seve1i ty of AEs 
PRAX-944 in pa1ticipants with ET • Change s in vital sign measurement s 
• Change s in clinical laborato1 y results 
• Change s in ECG pru·ameter s 
• Incidence of C-SSRS measured suicidal 
ideation or behavior 
Seconda1y 
• To evaluate the efficac y of PRAX-944 on • Change from Baseline to Day 42 in TETRAS 
upper limb tremor in pa1ticipants with ET Upper Limb score (bilateral sum of items 4a, 
4b, and 4c) 
• To evaluate the efficac y of PRAX-944 on • Change from Baseline to Day 7 and Day 21 
other measures of tremor severity in in TETRAS Upper Limb score (bilateral sum 
pruticipant s with ET of items 4a, 4b, and 4c) 
• Change from Baseline to Day 7, D ay 21, and 
Day 42 in the following: 
0 TETRAS Pe1fo1mance subscale total 
score 
0 Acce lerometer-ba sed upper limb score 
(bilateral sum of items 4a, 4b, and 4c) 
0 TETRAS Pe1fo1mance individual item 
scores 
Confiden tial Page 42 of84 
Prax is Precision Medicines 
Objective 
• To evaluate the efficacy of PRAX-944 on 
measures of disease impact in partic ipants 
with ET 
Explorato1y 
Confident ial Protocol PRAX-944 -221, Version 6.0 
Endpoint 
• Change from Baseline to Day 7, Day 21, and 
Day 42 in the following: 
o TETRAS ADL subscale score 
o Quality of Life in Essential Tremor 
Questionnaire (QUEST) total and 
subscale scores 
Page 43 of84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 44 of 84 Objective Endpoint  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 45 of 84 4. INVESTIGATIONAL PLAN  
4.1. Overall Design  
This multi- center clinical trial will assess the efficacy, safety, tolerability, and PK of PRAX -944 
in participants aged 18 years or older  who have had signs and symptoms consistent with  ET for 
at least 3 years, with an onset before age 65.  
The clinical trial will be conducted in 2 parts (Part A and Part B). Both parts will consist of 3 
periods: Screening/Baseline, Intervention, and Safety Follow -up. 
Part A  of the clinical trial is open -label and will assess the safety and tolerability of PRAX -944, 
as well as the overall magnitude and pattern of change in ET severity. Daily dose levels will be titrated from 20 mg to 40 mg.  
Part B of the clinical trial consists of both an open -label titration phase and a randomized, 
double- blind, placebo- controlled withdrawal phase. Part B will assess the safety and tolerability 
of PRAX -944, as well as the overall magnitude and pattern of change i n ET severity and the 
duration of that effect. Daily dose levels will be titrated from 20 mg to up to 120 mg during the 
open- label phase. In the randomized, double -blind, placebo- controlled withdrawal phase, 
participants will either be maintained on their final open- label dose or switched to placebo.  
Participants who received study drug in Part A are not eligible for Part B (see Exclusion 
Criterion #19).  
4.1.1.  Screening/ Baseline Period  
The Screening period for Part A and Part B will be up to 28 days (Day - 28 to Day -1). Fourteen 
additional days (ie, 42 days total) will be allowed in the Screening period for participants who 
are discontinuing primidone.  
Prior to any procedures, participants will provide written informed consent to participate in the 
clinical trial. Key Screening assessments will include medical history, demographics, physical 
examination, drug screen, clinical laboratory evaluations and serum pregnancy for women of 
childbearing potential, 12- lead ECG, vital signs, C -SSRS, assessment of ET severity using the 
TETRAS Performance subscale (including a video for independent review of eligibility), and a 
review of concomitant medications. To be eligible, potential participants who are taking 
prohibited medications will need to successfully discontinue the se medications for at least 5 
half-lives or 14 days prior (whichever is the longer period of time) before the first dose of study 
drug. 
For those participants requiring the 14 additional days in the Screening period to discontinue 
primidone, all or some of the Screening assessments may need to be repeated, pending approval 
by the Sponsor’s M edical Monitor. 
For participants in Part A , follo wing confirmation of eligibility, including review by the Sponsor 
or designee, participants will complete Baseline assessments (Day 0). Day 0 (Baseline) activities 
may be combined with Day 1 activities, provided that Baseline activities are completed befor e 
dosing and that dosing occurs in the morning of Day 1. In addition, Baseline efficacy 
assessments should either be conducted on Day 0 or Day 1 pre -dose, but not both to avoid 
learning effects.  
Praxis Precision Medicines Protocol PRAX -944-221, Version 6.0 
For participants in Part B, will also be completed with 
accelerometiy at Screening and via telehealth on D ay -2 of the Screenin eriod. The Screening 
telehealth visit is needed to ensure aiiici ants can com lete the 
Following 
confirm ation of e ligibility, inclu ding review by the Sponsor or designee, pa11icipant s will 
complete Baseline assessme nts (Day 1). Some B aseline assessme nts (as indicated in Table 3) 
may be completed on Day -1. 
4.1.2. Intervention Period 
4.1.2.1. Part A 
On D ay 1, participant s will receive a 20 mg dose of PRAX -944, admini stered in the mo rning. 
Paiiicipants will rema in in a clinical setting under medical observation for approximately 6 
hours. TETRAS Perfor mance assessme nts will be perfonned before dosing and again 6 hours 
post-dose. After the first dose, paiticipant s will continue QAM dosing at home after breakfa st 
throu gh Day 7. Participants will return to th e clinic on Day 7 for efficacy testing at the 20 mg 
dose level. On Day 8, the dose will increa se to 40 mg QAM after breakfast through D ay 14 for 
efficacy testing at the 40 mg d ose level. Participants will retmn to the clinic on D ay 14 for 
efficacy testing at the 40 mg d ose level. Participants who agree to optiona l additional PK 
samplin g will rema in overnight in the clinic on D ay 1, Day 7, and D ay 14. 
Key safety measures will include clinical laborato1 y evaluations, 12 -lead ECG , C-SS RS, and 
vital signs (Table 2). Key efficacy assessme nts will include the T ETRAS Perfo1mance subscale, 
(Table 2). Blood samples w ill be obtained for the determination of P RAX -944 plasma 
concentrations us ing a validated bioanalyt ical method and m ay also be u sed for explorato1 y 
method deve lopment and/o r metabo lite characterization. 
AEs and concomitant m edica tion use and proced ures will be mon itored from the time of 
info1med consent to Day 21 (±1 day). At that t ime, paiiicipants will have completed the c linical 
ti· ial. Paiiicipants who r eceived study dmg in Pa rt A ai· e not eligib le for Part B (see Exclusion 
Criterion #19). 
4.1.2.2. Part B 
4.1.2.2.1. Open-label Titration Phase 
On D ay 1, participants w ill receive a 20 mg dose of PRAX-944 on an e mpty stom ach ( at least 1 
hour before breakfast). Paiiici pants will remain in a clinical setting under medical observatio n 
for approx imately 6 ho urs. TETRAS Perfo1mance assess ments will be perfo1med before dosing 
and 6 ho urs (±2) post-dose. 
For dosing on D ay 2 through D ay 41, participants will be instmcted to dose QAM at least 1 hour 
before breakfast at hom e. 
Paiiicipants will continue taking P RAX -944 20 mg QAM at home through Day 3. 
On D ay 3, participants w ill receive a telephone call from site staff to inquire about AEs and 
concomitant medicatio ns, confnm dose escalatio n, and remind the pa11icipant about the number 
of stu dy drug tab lets to take on Day 4 through D ay 7. 
Confidential Page 46 of84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 47 of 84 On Day 4, participants will escalate to 40 mg QAM through Day 7, when they will return to the 
clinic for safety assessments and efficacy testing. On Day 8, participants should escalate to 
60 mg QAM through Day 14.  
On Day 14, participants will receive a telephone call from site staff to inquire about AE s and 
concomitant medications, confirm dose escalation, and remind the participant about the number of study drug tablets to take on Day 15 through Day 21.  
On Day 15, participants should escalate to 80 mg QAM through Day 21, when they will return to 
the clinic for safety assessments and efficacy testing. On Day 22, participants should escalate to 100 mg QAM through Day 28.  
On Day 28, participants will receive a telephone call from site staff to inquire about AE s and 
concomitant medications, confirm dose escalation, and remind the participant about the number 
of study drug tablets to take on Day 29 through Day 42.  
On Day 29, participants will escalate to 120 mg QAM through D ay 42, when they will return to 
the clinic for  safety assessments and efficacy testing.  The dose on Day 42 will be taken in the 
clinic (see Section 4.1.2.2.2  below). 
On Day 35, participants will receive a telepho ne call from site staff to inquire about AE s and 
concomitant medications.  
On Day 41, participants will complete a TETRAS Performance Upper Limb assessment via a 
telehealth visit.  
If at any point during the open -label titration phase a participant  does not tolerate escalation and 
the Investigator returns the participant to a lower dose  level, the participant will continue 
according to the schedule outlined above, but no further dose changes will be allowed. The 
Investigator should discuss the decision to continue at a lower dose level with the Sponsor and 
Medical Monitor. Participants can only change to a lower dose level once , and no dose changes 
may occur after Day 36.  
4.1.2.2.2. Double -blind Randomized Withdrawal Phase  
On Day 42, participants will complete the final clinic visit of the open -label titration phase. 
Participants will receive their dose of PRAX -944 administered in the clinic on an empty stomach 
(at least 1 hour before breakfast). Participants will remain in a clinical setting under medical 
observation for approximately 6 hours. TETRAS Performance assessments will be performed before dosing and 6 hours (±2) post -dose. 
After Day 42, participants will either continue receiving PRAX -944 at their current dose or 
switch to placebo, depending on their randomization. Randomization in a 1:1 fashion may be 
completed at any time on Day 37 through  42. 

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 48 of 84 4.1.3.  Safety Follow -up Period  
4.1.3.1.  Part A  
The Safety Fol low-up period will take place from Day 15 to Day 21. At the end of the Safety 
Follow- up period, participants will return to the clinic on Day 21  (±1 day)  for the final clinical 
trial assessments ( Table 2).  
4.1.4.  Clinical T ria
l Duration  
Participants will be part of the clinical trial for the following time intervals:  
4.1.4.1.  Part A  
Screening/Baselin e Period  Up to 28 days (+14 days if on primidone)  
Intervention Period  14 days  
Safety Follow -up Period 7 days  
Total Participation  Up to 49 days (63 days if on primidone)  
4.1.4.2.  Part B  
Screening/Baseline Period  Up to 28 days (+14 days if on primidone)  
Safety Follow -up Period 14 days  
Total Participation  Up to 98 days (112 days if on primidone)  
4.2. Scientific Rationale for Clinical Trial Design  
This is the first trial of PRAX -944 in ET.  
4.3. Justification for Dose  
The dose range of up to 120 mg QAM is based on the observed safety, tolerability and 
pharmacodynamic biomarker data in healthy volunteers. The was well 
tolerated at doses of up to 40 mg/day over 8 days in the z944- 104 study and 120 mg/day over 
4 days following a 27- day titration in the PRAX -944- 105 clinical trial. The titration completed in 
PRAX -944- 105 is nearly identical to the titration schedule used in this clinical trial.  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 49 of 84 4.4. Clinical Trial Committees  
The Sponsor will review ongoing safety data. The clinical trial may be stopped, or clinical trial 
enrollment suspended if:  
• The Sponsor, in consultation with the Principal  Investigators, consider that the 
number and/or severity of AEs justify discontinuation of the clinical trial  
• The Sponsor makes a decision to do so 
4.5. End of Clinical Trial Definition  
A participant is considered to have completed the clinical trial if he/she has completed the 
clinical trial intervention period including the last visit as shown in the Schedule of Activities 
(SoA).  
The end of the clinical trial is defined as th e date of the last visit of the last participant in the 
clinical trial.  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 50 of 84 5. POPULATION  
The intended population is participants with signs and symptoms of ET for at least 3 years who 
meet all eligibility criteria. If a participant’s signs and symptoms are judged by the investigator 
to be due to the diagnosis of ET, it is acceptable for them to also have one or more of the 
following ET plus signs:  
• Mild dystonic posturing  
• Mild rest tremor in the setting of advanced ET and in the absence of other features of Parkin sonism  
• Intention tremor  
• Mild increase in tandem gait difficulty  
The severity of these additional signs and the primary diagnosis of ET must be agreed upon by the central video reviewer.  
Source documentation should capture both the unlikely alternate diagnoses and the additional ET plus signs.  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Number of Participants  
5.1.1.  Part A  
Up to 12 participants are planned to be administered PRAX -944. 
5.1.2.  Part B  
Approximately 12 participants are planned to be administered PRAX -944 for the first 42 days 
followed by randomization (1:1) to 2 additional weeks on the highest tolerated dose of PRAX -
944 or placebo.  Up to 12 additional participants may be enrolled at the discretion of the Sponsor 
to ensure inclusion of a broad range of tremor severity.  
5.1.3.  Participant Replacement  
Participants who withdraw from either Part A or Part B prior to completion of the clinical t rial 
may be replaced at the discretion of the Sponsor. No more than 6 participants in either part of the 
study will be replaced.  
5.2. Inclusion Criteria  
A participant must meet the following criteria at Screening and Baseline (unless otherwise specified) to be eligible to participate in this clinical trial:  
I 1. Male or non- pregnant, non- lactating female aged 18 years or older . 
I 2. Willing and able to understand and sign an informed consent document indicating 
that he/she understands the clinical trial purpose, the clini cal trial procedures, and that 
he/she is willing to participate in the clinical trial and comply with the protocol.  
I 3. Body mass index (BMI) at  Screening between 18 and 40  kg/m
2, inclusive.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 51 of 84 I 4. Clinical diagnosis of ET consistent with Movement Disorders Society C riteria, a 
duration of ET of at least 3 years and with onset before the age of 65.  
I 5. Moderate to severe ET as defined by  the following : 
a. A combined bilateral score of ≥10 on the TETRAS Upper Limb  items 4 a, b, c. 
(UL tremor  severity at Screening will be confirmed by central video review, for 
eligibility ) 
OR 
b. A score of ≥ 2 on 2 or more of the following TETRAS activities of daily living 
(ADL) subscale items: (2) Feeding with a spoon, (3) Drinking from a glass, 
(5) Dressing, (6)  Pouring, (9) Writing  
OR 
c. A score of ≥ 2 on 1 of the following TETRAS ADL subscale items: (2) Feeding 
with a spoon, (3) Drinking from a glass, (5) Dressing, (6) Pouring, or (9) Writing  
AND a score of ≥ 2 on both of the following TETRAS ADL subscale items: 
(10) Working and (12) Social Impact  
Note:  ET severity at Baseline will be confirmed by the Investigator at the clinical trial site.  
I 6. Those currently receiving any medication for their ET must be willing a nd able to 
discontinue all but 1 tremor medication and be on a stable dose for at least 28 days.  
I 7. Willing to comply with medically acceptable method of contraception as defined in 
Section 5.4.3 . 
5.3. Exclusion Criteria  
A participant who meets any of the following criteria at Screening or Baseline (unless otherwise 
specified) will be excluded from this clinical trial:  
E 1. Known hypersensitivity to any component of the formulation of PRAX -944. 
E 2. Unwilling or unable to refrain from episodic use of medication(s)/substance(s) that 
might interfere with the evaluation of tremor during the trial. Stable use of 
medication(s)/substance(s) that might impact tremor, including  beta-agonist 
bronchodilators, is allowed so long as the tremor is judged by the investigator to be primarily due to the participant's ET diagnosis.  
E 3. Trauma to the nervous system within 3 months preceding the onset of tremor.  
E 4. Clinical evidence of psychogeni c tremor as ascertained by the Investigator.  
E 5. History of other medical, neurological or psychiatric condition that may explain or cause tremor, including but not limited to Parkinson's disease, dystonia, cerebellar 
disease, family history of Fragile X syndrome, traumatic brain injury, alcohol abuse or withdrawal, benzodiazepine abuse or withdrawal, multiple sclerosis, 
polyneuropathy and endocrine states such as hyperthyroidism.  
E 6. Prior magnetic resonance- guided focused ultrasound or surgical intervention for E T 
such as deep brain stimulation or thalamotomy.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 52 of 84 E 7. Botulinum toxin injection for ET in the 6 months prior to Screening.  
E 8. Unwilling or unable to discontinue primidone.  
E 9. Unwilling or unable to refrain from alcohol 24 hours before and during clinical trial 
visits. Or regular use of alcohol that would preclude abstinence from alcohol in this 
period, in the judgement of the Investigator.  
E 10.  Substance use disorder in the judgement of the Investigator  
E 11.  Sporadic use of a benzodiazepine, sleep medication or anxiolytic , that in the 
judgement of the Investigator or Sponsor would confound the assessment of tremor. Stable use at a consistent dose not exceeding the equivalent of 2 mg/day of lorazepam 
(see Section 6.5.2 ) is allowed as long as tremor persists against the background of 
regular medication use.  
E 12.  Use of prescription or non- prescription products and food known to be strong 
inhibitors or inducers of CYP3A4 or known to be a P -gp substrate (see Section 6.5.1 ) 
which cannot be discontinued at least 5 half -lives or 14 days prior (whichever is the 
longer period of time) and withheld throughout the clinical trial, including primidone.  
E 13.   The participant has any of the following at the Screening visit: a serum total bilirubin 
value >1.5× ULN; a serum  alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) value  >2×ULN. As an exception, participants that present 
with elevated bilirubin in the absence of elevations in ALT or AST that fits the patte rn of Gilbert’s syndrome may be enrolled after discussion with the medical 
monitor if their conjugated bilirubin is within the ULN.  
E 14.  Criterion removed from protocol in Version 5.0.  
E 15.  History of any suicide attempt within the past 2 years.  
E 16.  History of structura l heart disease (eg, congestive heart failure, depressed ejection 
fraction or left ventricular hypertrophy) or clinically significant cardiac arrhythmias 
(eg ventricular tachycardia) excluding sinus arrhythmia.  
E 17.  History of cancer treated with chemotherapy  
E 18.  Any other significant disease, disorder, lab abnormalities, or environmental factor 
that, in the opinion of the Investigator or Sponsor, may either put the participant at risk due to participation in the clinical trial, may influence or confound the result of the clinical trial, or affect the participant’s ability to participate in the clinical trial.  
E 19.  Has previously received treatment with PRAX -944 in any clinical trial (including 
Part A of the current trial for participants enrolling in Part B)  
5.4. Lifestyle Co nsiderations  
Participants must refrain from donating plasma, blood, or blood products (other than for this 
clinical trial) from Day - 1 until 93 days following last dose of study drug. Participants must 
refrain from adopting any new exercise programs during the trial.  
5.4.1.  Meals and Dietary Restrictions  
Grapefruits and grapefruit juice must be avoided during participation in the clinical trial.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 53 of 84 Participants should be instructed to refrain from alcohol 24 hours before and during clinical trial 
visits.  
For Part B on Day 1 and Day 42, PRAX -944 is to be administered in the clinic  on an empty 
stomach ( at least 1 hour before  breakfast). Only water and allowable concomitant medications 
are permitted prior to breakfast on Day 1 and Day 42.  For dosing on other days, parti cipants 
should be instructed to dose QAM at least 1 hour before breakfast.  
5.4.2.  Activity Restrictions  
Because PRAX -944 may cause sedation and dizziness, caution must be used in activities 
requiring mental alertness such as driving a car or operating heavy machi nery. This impairment 
may be made worse by other medications that also cause sedation or reduce alertness.  
5.4.3.  Contraception  
The effects of PRAX -944 on fetal development have not been ascertained. As such, all 
participants must agree to an approved form, or fo rms, of contraception. Participants will be 
provided information on acceptable methods of contraception as part of the informed consent 
process and will sign an informed consent form (ICF) stating  that they understand the 
requirements for avoidance of pregnancy, donation of ova, and sperm donation during and after 
the course of this clinical trial. The approved options are listed below. Every participant must agree to 1 of the 3 main options (1, 2 or 3):  
1. Male or female participants may agree to total (true)  abstinence (when this is in line 
with their preferred and usual lifestyle). Total (true) abstinence is defined as the strict 
avoidance of all forms of sexual activity. In males, this must extend from Day -1 through 90 days + 5 half -lives (ie, total of 93 days) after the last dose of study drug. 
In females, this must extend from Day - 1 through 30 days + 5 half -lives (ie, total of 
33 days) after the last dose of study drug. Periodic abstinence (eg, calendar, ovulation, symptothermal post -ovulation methods) a nd withdrawal are not acceptable 
methods. 
2. Participants do not need to use contraception if either they or their partner are sterile. 
Sterility is defined as follows: 
a. A female is considered to be surgically sterile if she has had 1 of the following 
procedur es: tubal ligation, tubal occlusion, hysterectomy, bilateral oophorectomy, 
or bilateral salpingectomy.  
b. A female is considered to be postmenopausal and sterile if it has been at least 2 
years since last regular menses and follicle -stimulating hormone  (FSH) >40 IU/L, 
or at least 5 years since last regular menses, confirmed before any study drug is administered.  
c. A male participant is considered sterile if he is at least 1 -year post vasectomy and 
has obtained documentation of the absence of sperm in their ejaculate.  
3. If neither option 1 nor option 2 criteria are met, then the participant must agree to using a combination of 2 of the highly effective methods listed below (a+a, a+b or 
a+c or b+c):  
a. Barrier contraception with or without spermicide, eg, male condom or female 
diaphragm with or without spermicide (foam, gel, film, cream, or suppository);  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 54 of 84 b. Use of oral, injected, or implanted hormonal methods of contraception or other 
forms of hormonal contraception that have comparable efficacy;  
c. Placement of an in trauterine device or intrauterine system.  
Note:  
• A participant can agree to using 2 methods, 1 of which is primarily dependent on their 
partner. For example, a male participant can agree to a barrier with spermicide and for his female partner to use oral hormonal contraception. Similarly, a female participant 
can agree to using oral hormonal contraception and for her male partner to use a barrier with spermicide.  
• Male participants must use 2 highly effective methods from Day - 1 through 90 days + 
5 half -lives  (3 days) after the last dose of study drug (ie, 93 days).  
• Female participants must use 2 highly effective methods from Day - 1 through 30 days 
+ 5 half -lives (3 days) after the last dose of study drug (ie, 33 days).  
5.4.4.  Sperm and Ova Donation  
• Male participants  must refrain from sperm donation from Day - 1 through 90 days + 5 
half-lives (+3 days) after the last dose of study drug.  
• Female participants must refrain from ova donation from Day - 1 through 30 days + 5 
half-lives (+3 days) after the last dose of study drug.  
5.5. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical trial but are not subsequently entered in the clinical trial. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants. Minimal information 
includes demography, screen failure details, eligibility criteria, and any SAE.  
Individuals who do not meet the criteria for participation in this clinical trial (screen failure) may be rescreened after  consultation with the Sponsor and Medical Monitor.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 55 of 84 6. CLINICAL TRIAL INTERVENTION 
Clinical trial intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a clinical trial participant according 
to the clinical trial protocol.  
6.1. Study Drug(s) Administered  
20 mg PRAX -944 or matching placebo will be administered orally and provided in 
pre-packaged containers to the participants.  
6.1.1.  Part A  
All participants will receive PRAX -944 orally, 20 mg QAM for 7 days and 40 mg QAM for 7 
days. 
6.1.2.  Part B  
6.1.2.1.  Open -label Titration  
The planned titration schedule for  PRAX -944 is as follows : 
• 20 mg QAM for 3 days  
• 40 mg QAM for 4 days  
• 60 mg QAM for 7 days  
• 80 mg QAM for 7 days  
• 100 mg QAM for 7 days  
• 120 mg QAM for 14 days  
-
Praxis Precis ion Medicines Protocol PRAX -944-221, Vers ion 6.0 
Table 4: Study Drug Information 
ARM Name 
Intervention Name 
Type 
Dose Formulation 
Unit Dose Strength(s) 
Dosage Level (s) 
Route of 
Administration 
Sourcing 
Packaging and 
Labeling 
Confidential Open-Lab el Part A 
• 20 mgQAM 
Day 1 through Day 7 
• 4 0mgQAM 
Day 8 through Day 14 Open-label Part B 
PRAX -944 
Drug 
Modi fied-release tablet 
20mg 
• 20mgQAM 
Day 1 through Day 3 
• 40mgQAM 
Day 4 through Day 7 
• 60 mgQAM 
Day 8 through Day 14 
• 80mgQAM 
Day 15 through Day 21 
• 100 mg QAM 
Day 22 through Day 28 
• 120mgQAM 
Day 29 through Day 42 Double-blind PRAX-944 
• 120 mg or highest 
tolera ted dose QAM 
Day 43 through Day 56 
Oral 
Provided centrally by the Spon sor Double-blind Placebo 
Placebo 
Placebo 
Tablet 
Placebo 
• Placebo QAM 
Day 43 through Day 56 
None 
Study drug will be provided in pre-packaged containers. Each container w ill be labeled as required per country 
requiremen ts. 
Page 56 of84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 57 of 84 6.2. Preparation/Handling/Storage/Accountability 
The following requirements for handling, storing, and accounting for study drug must be 
followed: 
6.3. 1. The Investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study drug received and any discrepancies are 
reported and resolved before use of the study drug.
2. Only participants enrolled in the clinical trial may receive study drug and only 
authorized site staf
f may supply or administer study drug. All study drug must be 
stored in 
a secure, environmentally controlled  area in accordance with the labeled  
storage conditions with access limited to the Investigator and authorized site staff.
3. The Investigator,
 institution, or the head of th e medical institution (where applicable)  
is responsible for study drug accountability, reconciliation, and record maintenance  
(ie, receipt, reconciliation, and final disposition records).
4. Further guidance and information, including for the final disposition of unused study 
drugs are provided in the Pharmacy
 Manual.
Randomization and Blinding
This trial includes both open- label (unblinded) and double -blind phases.  
Study drug will be dispensed at the clinical trial visits as summarized in the SoA ( Table  2 and 
Table 3). Re turned study drug must not be re -dispensed. 
Randomization in a 1:1 fashion to one of these groups may be completed at any time on Day 37 
through 42. The assignments will be blinded to all participants, Investigators, site personnel, and 
Sponsor personnel.  
Replacement randomization numbers will be used as needed for any participant that is replaced 
in Part B.  
6.3.1.  Breaking the Blind  
In the event of a medical emergency, where knowledge of the study drug assignment is needed to medically treat the participant, the treatment assignment of an individual participant can be 
obtained via code break envelopes. Whenever possible, the Principal  Investigator should consult 
with the Medical Monitor or the Sponsor Medical Director prior to unblinding a participant. If 
that is not possible, the Investigator may unblind to treat a medical emergency without 
consultation. Code breaks must be promptly communicated to the Medical Monitor and Sponsor Medical Director and detailed in the source documentation.  
6.4. Study Drug Compliance  
Participant compliance with study drug will be assessed at each visit. Compliance will be 
assessed throughout the clinical trial  by participant reporting, measuring plasma exposure, and 
return of used and unused PRAX -944 containers. This clinical trial will also employ a 
medication adherence monitoring platform (“Platform”). The Platform uses artificial intelligence 

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 58 of 84 on smartphones to confirm medication ingestion. In addition, built -in reminders and a 
communication system allow real- time intervention in case of drug interruptions.  
Deviation(s) from the prescribed dosage regimen should be documented.  
6.5. Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving from 30 days prior to Screening or 
receives during the clinical trial must be recorded along with:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency of administration  
The Medical Monitor should be contacted if there are any questions regarding concomitant or prior therapy.  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 59 of 84 6.5.2.  Permitted Med
ications  
Participants may take only 1 concomitant medication for their ET and must be on stable doses of 
that 1 medication for at least 28 days  prior to Screening in the clinical trial. Stable use at a 
consistent dose not exceeding the equivalent of 2 mg/day of lorazepam is allowed as long as 
tremor persists against the background of regular medication use (sporadic use of a 
benzodiazepine, sleep  medication or anxiolytic, that in the judgement of the Investigator or 
Sponsor would confound the assessment of tremor, is not allowed). Concomitant use of 
allowable benzodiazepines must be limited to a daily dosage equivalent of 2 mg of lorazepam 
(refer to Appendix 3).  
6.6. Dose Modification  
No dose modifications are permitted in Part A or the Part B double-blind randomized w ithdrawal 
phase.  
In the Part B open -label titration phase, participants may return to a lower dose of PRAX -944 
after escalating due to tolerability or safety concerns. The Investigator should discuss the 
decision to continue at a lower dose level with the Sponsor and Medical Monitor. Participants 
can only change to a lower dose level once. No dose changes are permitted after Day 36.  
The S ponsor may discontinue any dose of PRAX -944 based on ongoing monitoring of safety and 
tolerability.  
6.7. Intervention After the End of the Clinical Trial  
There is no intervention following the end of the clinical trial. Participants will continue to 
receive standard of care for what is normally expected for their condition.  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 60 of 84 7. DISCONTINUATION OF STUDY DRUG AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuation of Study Drug  
In rare instances, it may be necessary for a participant to permanently discontinue study drug. If 
study drug is permanently discontinued, the participant will remain in the clinical trial to be 
evaluated for safety and efficacy. See the SoA for data to be collected at the time of early 
termination for each part, if applicable.  
7.1.1.  Temporary Discontinuation 
Temporary discontinuations of study drug is allowed on a case -by-case basis, pending approval 
from the Sponsor.  
7.1.2.  Rechallenge 
Rechallenges of study drug are allowed on a case -by-case basis in Part A, pending approval from 
the Sponsor.  
One dose reduction is permitted in Part B but thereafter rechallenge is not allowed. No dose changes after Day 36 are allowed.  
7.2. Participant Discontinuation/Withdrawal from the Clinical Trial  
A participant may withdraw from the clinical trial at any time at his/her own  request or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons. This is expected to be uncommon.  
At the time of discontinuing from the clinical trial, if possible, an early termination visit should 
be conducted, as shown in the SoA. See SoA for data to be collected at the time of clinical trial discontinuation and follow -up and for any further evaluations that need to be completed for each 
part. 
If the participant withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the clinical trial, he/she may request destruction of any samples taken and not tested, and the Investigator must document this in the site clinical trial records.  
Participants who do not complete 14 days of study drug in Part A or 56 days of study drug in Part B or do not complete their scheduled safety, efficacy, or PK assessments may be replaced to 
ensure a sufficient number of participants are evaluable.  No more than 6 participants in either 
part of the study will be replaced.  
7.3. Lost to Follow -Up 
A participant will be considered lost to follow -up if he or she repeatedly fa ils to return for 
scheduled visits and is unable to be contacted by the clinical trial site.  
The following actions must be taken if a participant fails to return to the clinic for a required 
clinical trial visit:  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 61 of 84 • The site must attempt to contact the partic ipant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the clinical trial.  
• Before a participant is deemed lost to follow -up, the Investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address or  local equivalent methods). These contact attempts should be documented 
in the participant’s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the clinical trial.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 62 of 84 8. CLINICAL T RIAL AS SESSMENTS AN D PROCEDURES
Clinical trial procedures a nd their timing  are summ arized in the  SoA  (Table 2 a nd Table 3). 
P
rotocol waivers or exemptions are not allowed. 
Immediate safety concerns should be discussed with the Sponsor immediately upon occ urrence 
or awareness to determine if the par ticipant should continue or discontinue study drug. If thi s 
discussion is not possible and the concern is urge nt, the Investigator may discontinue study drug 
w
ithout consultation, but these situations are expected to be rare. 
A
dherence to t he clinical trial de sign requirements, including those specified in the SoA, is 
essential and  req uired f or clinical t rial cond uct.  
All Screening evaluations must be completed and reviewed to confirm that potential participants 
meet all eligibility criteria. The Investigator will maintain a screening l og to record details of all 
participants screened and to confirm eligibility or record reasons for screen failure, as applicable.  
Procedures conducted as part of the part icipant’s routine clinical management (eg, blood count) 
and obtained before si gning of the IC F may be utilized for Screening or Baseline purposes 
provided the pr ocedures meet the protocol -specified cr iteria and  were performed w ithin t he ti me 
frame defined in the SoA (Table 2 a nd Tabl e 3). 
For Part A, the am
ount of blood collecte d from each participant over the dur ation of the clinical 
trial, including any extra assessments that may be required, will be approximately 50 mL w ith 
spars
e sampling for PK or 180 mL with seri al sampling for PK. Repeat or unscheduled samples 
may be  taken
 for safety reasons  or for technical i ssues w i th the samples. 
For Part B, the amount of blood collecte d from ea ch participant over the duration of the clinical 
trial, including any extra assessments that may be required, will be approximately 115 mL. 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples. 
A suggested order of assessments for Part B is provided in the Assessment Manual. 
8.1. Efficacy Assessments  
Planned time p oints for all efficacy assessments are provided in the SoA ( Table 2 and Table 3). 
Efficacy will be measured using the following instruments:  
8.1.1.  TETRAS  
The TETRAS was developed by the Tremor Research Gr oup (TRG; 
www.tremorresearchgroup.org) to quantify ET severity and its impact on ADLs. This scale 
requires only pen and paper and can be complete d in about 10 minutes. The full scale has 2 
sections, t he Performance and  AD L s ubscales, w hich ar e hi ghly cor related.  Upper ext remity 
action  tremor  is the  main focus of both parts of  this scale s ince it is th e ma in sour ce of disa bility. 
However
, action tremor  is also as sessed i n the head,  face, voi ce, and  lower l imbs. The  TETRAS 
scale de
monstrated f ace validity,  inter- and intra -rater r eliability, a nd sensitivity to change ( Elble 
2016). 
For Part B, TETRAS can be completed anytime at Screening and Day 70. On other days, the 
following timing should be followed: 
•Day 1: pre -dos
e and 6 (±2) hours after a 20 mg QAM dose
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 63 of 84 • Day 7: 6 (±2) hours after a 40 mg QAM dose  
• Day 21: 6 (±2) hours after an 80 mg (or highest tolerated dose) QAM dose  
• Day 42: pre -dose and 6 (±2) hours after a 120 mg (or highest tolerated dose) QAM 
dose 
• Day 56: 6 (±2) hours post -dose 
For visits with multiple TETRAS assessments, the TETRAS ADL subscale should only be 
assesse d once. On Day 1, the ADL subscale should be completed pre- dose. On day 42, the ADL 
subscale should be completed 6 (±2) hours after the QAM dose.  
8.1.1.1.  Performance Subscale 
There are 9 items covering different body regions in the Performance subscale. Each Performance subscale item is rated on a scale of 0 to 4, with higher scores indicating higher 
tremor severity. Item 4 of the Performance subscale is the upper limb item. It is comprised of 6 sub-items (4a, 4b, and 4c assessed for both the right and left upper limbs). The P erformance 
subscale score is calculated as the sum of all 9 items and ranges from 0 to 64. Toward 
interpreting certain items (eg, Archimedes Spirals, handwriting and dot approximation), it is important to note whether the participant’s dominant  hand is their left or their right.  
8.1.1.2.  Upper Limb Item  
Item 4 of the Performance subscale is the upper limb item. For this item, 3 tasks are performed 
on each side of the body: 4a) postural tremor with upper limbs held forward and horizontally, 4b) 
postural tremor with upper limbs extended laterally and horizontally, with the elbows flexed and 
hands positioned close to each other near the chin (“wing beating position”), and 4c) kinetic tremor during finger -nose (or chin) -finger movements. As each of the upper limb items is rated 
independently for the right and left side of the body, the upper limb item is comprised of 6 sub-items. Each sub -item is rated on a scale from 0 to 4, with higher scores indicating higher 
tremor amplitude of the upper limb. The upper limb total score is the sum of these 6 sub- items 
and ranges from 0 to 24.  
The upper limb item will be assessed via clinician, Kinesia ONE (accelerometer), and video rating by an independent rater. The initial assessment of the upper limb item will be perform ed 
by the clinician with each task being performed for each side. The participant will then perform the same tasks while wearing an accelerometer. The accelerometer will record rotations and accelerations in the 3D space over time. As with the clinician assessment, each task will be 
performed for each side first for the right arm and then for the left. For the purposes of 
confirming eligibility, an independent central rater  will score a video of the initial assessment 
described above . 
For Part B, Kinesia ON E assessments must be completed immediately after the TETRAS 
Performance assessments (including both pre -dose and post -dose assessments on Day 1 and 
Day 42). Kinesia ONE assessments should be completed twice at each timepoint with the 
2 assessments separat ed by at least 30 minutes.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 64 of 84 8.1.1.4.  TETRAS T
elehealth Assessment  
The TETRAS Performance subscale upper limb item (item #4) will be conducted by the site rater 
using televideo technology while the participant is at home. The pu rpose of this assessment is to 
compare upper limb item scores obtained via a telehealth visit to scores obtained in the clinic to 
assess the reliability of telehealth assessments.  
8.1.1.5.  TETRAS Activities of Daily Living  (ADL)  
The TETRAS ADL subscale is a 12- item assessment of typical daily activities that are impacted 
by tremor. Activities are assessed in the following functional domains: speaking, feeding, 
drinking, personal hygiene, dressing, writing, and social activity. The impact to each function is rated on a 5 -point Likert scale from 0 to 4. The ADL subscale score is calculated as the sum of 
all 12 items and ranges from 0 to 48.  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 65 of 84 8.1.4.  Quality of Life in Essential Tremor Questionnaire (QUEST; Part B Only ) 
The QUEST is a brief, 30- item, patient- reported ET -speciﬁc quality of life s cale. The scale 
contains 5 subscales that cover physical, psychosocial, communication, hobbies/leisure, and 
work/finance dimensions. The individual items are rated either on a 5- level Likert scale from 0 to 
4 (never, rarely, sometimes, frequently, always) or a 2 -level scale from 0 (no) to 4 (yes) relative 
to the respondent's current situation. Five items could also be rated as not applicable . 
Respondents are also asked to indicate which tremor was perceived to impact a function or be associated with the feeling or attitude in question . The QUEST total and subscale scores are 
calculated as the sum of all applicable items divided by the number of applicable items times 
100. 
8.2. Safety Assessments 
Planned time points for all safety assessments are provided in the SoA ( Table 2  and Table 3). 
AEs will be evaluated and reported ( Section 8.4). Safety will be assessed as described below.  
8.2.1.  Physical Examinations  
A complete physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, gastrointestinal, and neurological systems. Height and weight will also be measured and recorded (at Screening only).  
8.2.2.  Vital Sign Measurements  
This assessment will measure changes in vital sign measurements, specifically of the following:  
• Temperature, pulse rate, respiratory rate, and blood pressure will be assessed.  
• Blood pressure (systolic and diastolic) and pulse measurements will be preceded by at 
least 5 minutes of rest, in a quiet setting without distractions (eg, tablets, television, 

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 66 of 84 mobile phones). These measurements will be assessed after the participant has been 
supine for at least 5 minutes, and standing for at least 2 minutes.  
8.2.3.  Electrocardiograms  
This assessment will measure changes in ECG parameters, specifically:  
•ECGs will be obtained as outlined in the SoA using an ECG machine that
automatically calculates the heart  rate and measures PR, QRS, QT, and QTc intervals.
ECGs will be read centrally.
•Triplicate measurement will be taken at Screening only; for all other timepoints,single measurement is acceptable. When triplicate ECGs are required, 3 individualECG tracings should be obtained as closely as possible in succession, but no more
than 2 minutes apart.
8.2.4.  Clinical Safety Laboratory Assessments  
This assessment will measure changes in laboratory values, specifically:  
•The Investigator must review the laboratory report, document this review, and record
laboratory values. Any clinically significant, adverse changes occurring during the
clinical trial should be documented as AEs. Lab oratory- assessment  related AEs
should be documented and follow as with other AEs.
•All laboratory tests with values considered clinically significantly abnormal during
participation in the study drug should be repeated until the values return to normal orbaseline or are no longer considered clinically significant by the Investigator or
Medical Monitor.
•Clinically significant abnormal laboratory findings are those which are not associated
with the underlying disease, unless judged by the Investigator to be more severe than
expected for the participant's condition.
•See Appendix 1 for the list of clinical laboratory tests to be performed and to the SoA
(see Table 2 and Table 3) for the timing and frequency.
Refer to the Laboratory Manual for additional details on sample handling and processing. 
8.
2.4.1.  Monitoring for Safety Laboratory  Assessment s of Special  In terest 
Renal function monitoring will be based on the Kidney Disease Im proving Global Out comes 
(KDIGO) guidelines and criteria for acute kidney injury (AKI)(Kellum 2012) . According to the 
KDIGO guidelines, AKI is defined as any of the following: 
•Increa
se in SCr by ≥0.3  mg/d L (≥26.5 µmol/ L) within 48 hours ; or
•Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred
within the prior 7 days
If a participant’s  laboratory values exceed these thresholds, dosing of that participant will be 
stopped and the laboratory tests will be repeated. Pending the results of these tests, a discussion will occur to determine pausing, stopping or continuing dosing the specific participant and/or the 
remainder of the participants in the study. Throughout the duration of the clinical trial, 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 67 of 84 participants should immediately notify the study team i f there are any significant changes in their 
urine frequency or volume.  
8.2.5.  Columbia -Suicide Severity Rating Scale (C -SSRS) Measurements  
The C -SSRS was developed by researchers at Columbia University as a tool to help 
systematically assess suicidal ideation an d behavior in participants during participation in a 
clinical trial of centrally -acting drugs (Posner 2011) . The C -SSRS is composed of 5 questions 
addressing suicidal behavior and 5 questions addressing suicidal ideation, with sub-questions 
assessing the severity. Two versions of the C -SSRS will be used in this clinical trial: the 
Baseline/Screening Version (at the Screening visit) and the Since Last Visit Version (at all other visits). It takes approximately 5 to 10 minutes to administer the C -SSRS. The t ool should be 
administered via interview with the participant (by a trained operator/interviewer).  
8.3. Pharmacokinetic Assessments  
Blood sam
ples will be colle cted for measurement of blood concentrations of PR AX-944 as 
specified in the SoA (Table 2 and Tabl e 3). Samples col lected m ay al so be  used t o eval uate 
safety or  eff icacy as pects r elated t o conc er ns  arising dur ing or af ter t he cli nical t rial. PRAX -944 
plasma samples may also be used for additional exploratory method deve lopment and/or 
metabolite characterization purposes. 
Refer to the Laboratory Manual for additional details on sample handling and processing. 
8.4. Adverse and Serious Adverse Events  
The definitions of an AE or SAE can be found in Appendix 2. 
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative).  
The Investigator and any qualified designees are responsible for detecting, documenting,  and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study drug or clinical trial procedures, or that 
caused the participant to discontinue the clinical trial . 
8.4.1.  Time Period and Frequency for Collecting AE and SAE Information  
All AE and SAE information will be collected from the signing of the ICF until the end of the 
clinical trial at the time points specified in the SoA.  
All SAEs and AEs of special interest wil l be recorded and reported to the Sponsor or designee 
immediately and under no circumstance should this exceed 24 hours, as indicated in Appendix 2. 
The Investigator will submit any updated SAE data to the Sponsor within 24 hours of it being 
available.  
8.4.2.  Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in Appendix 2.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 68 of 84 Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open- ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences.  
8.4.3.  Follow- up of AEs and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follo w each 
participant at subsequent visits/contacts. All SAEs  and AEs of special interest will be followed 
until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow -
up. Further information on follow -up procedures is given in Appendix 2.  
8.4.4.  Regulatory Reporting Requirements for SAEs  
Prompt notification by the Investigator to the Sponsor of an SAE is essential so th
at legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
drug under clinical investigation are met. 
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study drug under clinical investigation. The Sponsor will 
comply w
ith country-specific regulatory requirements relating to safety reporting 
to the regulatory 
authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and 
Investigators. 
Investigator safety reports must be prepared for suspected unexpected  serious adverse reactions 
(SUSAR) according to local regulatory requirements and Sponsor policy and forwarded to 
Investigators as necessary. 
An Investigator who receives an investigator safety report describing an 
SAE or other specific 
safety information (eg,
 summary or listing of SAEs) from the Sponsor will review and then file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements. 
8.4.5.  AEs
 of Special Interest  
Any event of sei zure, seizure- like phenomena, loss of consciousness, altered state of 
consciousness, tardive dyskinesia, acute dystonic reactions, akathisia, or acute Parkinsonian 
symptoms (eg, bradykinesia, tremor, cogwheel rigidity, mask- like faces) will be regarded as an 
adverse event of special interest in this trial and must be reported to the Sponsor within 24 hours.  
8.4.6.  Pregnancy  
Details of all pregnancies in female participants and female partners of male participants will be 
collected after the start of study drug through completion of the pregnancy.  
If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of 
learning of the pregnancy.  
Male participants will be instructed via the ICF to immediately inform the Investigator if their female partner becomes pregnant  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 69 of 84 8.4.7.  Disease -Related Events and/or Disease- Related Outcomes Not Qualifying as AEs 
or SAEs  
Fluct uations of individual items on the efficacy assessments that are consistent with the typical 
course of ET should not be interpreted as worsening or improvements of the overall condition. 
Changes in disease severity should be determined by the Investigator based on an assessment of the participant’s overall condition.  
8.6. Treatment of Overdose  
The Sponsor does not recommend specific treatment for an overdose and care should be 
supportive in keeping with local institutional practices.  
In the event of a documented or suspected overdose, the Investigator/treating physician should:  
•Ensure the participant receives necessary medical care
•Contact the Medical Monitor immediately
•Closely monitor the participant for any AE/SAE, including laboratory abnormalities
The effec
ts of overdose of PRAX -944 are unknow n. As such, no specif ic antidote for PRAX -944 
overdose is know n. Although it is not expected that overdose will occur in this clinical trial, 
participants should be managed with appropriate supportive care should overdose with 
PRAX-944 inadvertently occur. Please also see the mitigation of overdose risk Section 6.10 in 
th
e IB
. 
Risks unrelated to PRAX -944 include thos e from collection of blood samples, including 
bruising, pain at the site, swelling, redness, bleeding, or infection. 
8.7. Genetics  
Genetics are not evaluated in this clinical trial.  
8.8. Health Economics/Medical Resource Utilization and Health 
Economics 
Health Economics/Medical Recourse Utilization and Health Economics parameters are not 
evaluated in this clinical trial.  

Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 70 of 84 9. STATISTICAL CONSIDERATIONS  
This section outlines the general statistical methods contributing to the clinical trial design and 
planned analysis of clinical trial data. A comprehensive st atistical analysis plan (SAP) will be  
developed and finalized prior to database lock and will provide a more detailed description of analysis sets, endpoint derivations (including any procedures for missing data), and analysis 
methods (including mock tables and listings).  
9.1. Sample Size Determination  
The sample size of each part (up to 12 participants) is a convenience sample. The sample size 
was not selected according to any statistical power calculation. Instead, the sample size was determined according to feasibility and is thought to provide sufficient efficacy and safety data to 
inform the development of future controlled studies with PRAX -944 in participants with ET. 
Part B sample size may be increased to up to 24 participants to ensure inclusion of a broad range 
of tremor severity. In the open- label phases of the trial (Part A and Part B, open -label titration), a 
sample size of at least 10 participants would provide an 80% probability of observing at least 1 
AE with an underlying incidence of 15% or greater. In addition, 10 participants should also provide approximately 80% power to detect an effect size of 1.0 on the primary endpoint of 
change from Baseline in TETRAS Upper Limb  score.  
9.2. Populations for Analyses  
All data analyses will be performed using at least 1 of the following analysis sets.  
Analysis Set  Description  
Enrolled Analysis Set  All participants who sign an ICF and are provided with an enrollment 
number. The Enrolled Analysis S et will be used for all participant 
disposition analyses.  
Safety Analysis Set  All participants who received at least 1 dose of study drug. Participants 
will be classified according to actual intervention received. The Safety 
Analysis S et will be used for all demographic, baseline characteristics, 
prior/concomitant medication, study drug exposure, and safety analyses.  
Full Analysis Set  All participants who took at least 1 dose of study drug and have a valid baseline TETRAS assessment and at least 1 valid post -baseline 
TETRAS assessment. The F ull Analysis S et will be used for the 
analysis of all efficacy data.  
PK Analysis Set  The PK Analysis Set includes all participants who received at least 1 
dose of study drug and have at least 1 evaluable plasma concentration. The PK Analysis Set will be used for the analysis of plasma 
concentrations and PK parameters.  
9.3. Statistical Analyses  
The SAP will be developed and finalized prior to database lock and will describe the participant 
populations to be included in the analyses, and procedures for accounting for missing, unused, 
and spurious data. For all data displays, separate summaries will be generated for each part of the 
clinical trial. For the randomized portion of Part B, data will be summarized by the randomized 
Praxis Preci sion Medicines Protocol PRAX- 944-221, Version 6.0 
continuation ti·eatment. Safety , tolerability , PK and efficacy variable s will be summarized using 
descript ive statist ics. Descriptive sUIIllnar ies for categor ical variab les will includ e counts and 
percentage. Descriptive summar ies for continuous variables will include numb er of participants 
(n), mean, standard deviation (SD) , median , minimum, and maximum. Where appropriate , 95% 
confidenc e intervals (Cls) may be reported . Summaries will be presented by time point, where 
approp riate. 
Unless specified othe1wise , all data recorded will be listed by pa1ticipant. 
9.3.1. Efficacy Analyses 
Reported values and change from baseline values in TETRAS Upper Limb score , TETRAS 
Perfonnance subscale total and individ ual scores, TETRAS Upper Limb accelerometer score, 
TETRAS Upper Limb telehealth score , TETRAS AD L Subsca le score , , QUEST 
total and subsca le scores, will be 
summarized by time point. In additio scores will also be analyzed using 
paired t-tests or similar methods. For , repo1ted values will be 
summarized by time point. 
9.3.2. Safety Analyses 
Adverse event data will be coded using the Medical Dicti onaiy for Regulatory Activities 
(MedDRA) . The number and percentage of paiticipants expe rienc ing any ti·eatment-emergent 
AE (TEAE ) will be summai·ized by system organ class (SOC) and prefened tenn (PT). In 
addit ion, TEAEs will be sUIIlln arized siinilarly by maximum severity and maximum relationsh ip 
to PRAX-944 . SAEs and TEAEs leading to disco ntinuation of PRAX-944 will be listed . 
Reported values and change from baseline values in vital signs, ECG parameters , and 
hematology and clinical chemistiy laborato1y pai·ameters will be sUIIllnai ·ized by time point. 
For the C-SS RS, the incidence of suicidal ideation/behavio r at any time will be sUIIllnai ·ized for 
each C-SSRS ideation , behavior , and ideation/behavior indic ator. 
9.3.3. Pharmacokinetic Analyses 
For Pait A, standa rd PK parameters will be estimated using non compa1tme ntal methods based on 
the concenti·ation-time data. These parameters will inclu de, where possible , Cmax, T max, t112, 
AUCo-tau , CL/F, and Vd/F. Explorato 1 y analyses examining the relationship betwee n PK and 
efficacy parameters may be perfonned for the PK Analysis Set. 
The PK parameters described ai·e those nonnally calcu lated for this type of clinical trial; 
however , the actual parameters calculated may vaiy depending on the availability and viability of 
the data obtained. Other parameters may be added as appropr iate. Final PK parameters to be 
repo1ted will be detai led in the SAP or a separate PK analys is plan. 
9.3.4. Other Analyses 
PK and selected efficacy data. may be utiliz ed in a population PK analysis , which will be 
presented separate ly from the main clinical study repo1t (CSR). 
Confident ial Page 71 of 84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 72 of 84 9.3.5.  Interim Analyses  
No formal interim analysis is planned for this clinical trial.  Clinical trial data from Part A and 
open- label data from Part B will be reviewed on an ongoing basis.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 73 of 84 10. REGULATORY, ETHICAL, AND CLINICAL TRIAL 
OVERSIGHT CONSIDERATIONS  
10.1. Regulatory and Ethical Considerations  
This clinical trial will be conducted in accordance with this protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International  Ethical Guidelines  
• Applicable International Council for Harmonisation ( ICH) Good Clinical Practice 
(GCP) Guidelines  
• Applicable laws and regulations  
The protocol, protocol amendments, ICF, IB, and other relevant documents (eg, advertisements) 
must be submitted to an IRB/IEC by  the Investigator and reviewed and approved by the IRB/IEC 
before the clinical trial is initiated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the clinical trial design, except for changes necessary  to eliminate an immediate 
hazard to clinical trial participants.  
The Investigator will be responsible for the following:  
• Providing written summaries of the status of the clinical trial to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC  
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures  
• Providing oversight of the conduct of the clinical trial at the site and adher ing to 
requirem ents of ICH guidelines, the IRB/IEC, and all other applicable local 
regulations 
10.2. Financial Disclosure  
Investigators and sub- Investigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the clinical trial 
and for 1 year after comp letion of the clinical trial.  
10.3. Informed Consent Process  
The Investigator or his/her representative will explain the nature of the clinical trial to the 
participant or his/her legally authorized representative and answer all questions regarding the 
clinical trial.  
Participants must be informed that their participation is voluntary. Participants will be required to 
sign a statement of informed consent that meets the requirements of local regulations, ICH 
guidelines, and the IRB/ IEC or clinical trial c enter.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 74 of 84 The medical r ecord m ust include  a statement  that  written i nformed cons ent was obt ained  before 
the participa
nt was e nrolled in the  clinical t rial and  the date the  written c onse nt was obt ained.  
The authorized person obtaining the inf ormed consent must also sign the ICF. 
Participa
nts mus t be re-consented to the most cur rent version of the ICF(s) during their 
participation  in the  clinical trial.  
A copy of the IC F(s) must be provided to the participant or the participant’s legally authorized 
representative. 
10.4. Data P rotection 
Participants will be assigned a unique identifier by the Sponsor. Any participant records or 
da
tasets that are transferred to the Sponsor will contain the identifier only; participant names or 
any information whi ch would make the participant identifiable will not be transferred. 
The par ticipant  must be inf ormed tha t his/her pe rsona l clinical trial- related  data will be  used by  
the Sponsor in ac
cordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The par
ticipant must be informed that his/her me dical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory author ities. 
10.5. Data Quality Assurance 
All participa
nt data r elating  to the  clin ical trial w ill be  recorded on  printe d or ele ctronic case 
report fo rms ( eCRFs) unless transmitted to the Sponsor or de signee electronicall y (eg, laboratory 
data). The Investigator  is responsible for  verifying  that da ta ent ries ar e accurate and  corr ect by  
physically or el ectronically signing the case report f orm ( CRF). 
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
The Inve stigator  must permit c linical trial- related monitoring, audits, IRB/IEC re view, and 
regulatory agency inspections and pr ovide direct access to sour ce da ta documents. 
Monitoring details describing strate gy (eg, risk-based initiatives in operations and quality suc h as 
Risk M anagement and  Mitigation  Strategies a nd Analytical Risk- Base d Monitoring), methods, 
responsibilities and requirements, including handling of noncompliance issues and monitoring 
techniques (central, remote, or on-site monitoring) are provided in the Monitoring Plan. 
The Sponsor or desi
gnee is responsible for the data management of this clinical trial including 
quality checking of the data. 
The Spons
or assumes accountability for actions delegated to other individuals (e g, Contract 
Research O rganizations). 
Clinical trial monitors w ill perform ongoing  source da ta ve rification  to confirm tha t data e nt ered 
into the CRF by aut
horiz ed site personnel a re accurate, co mplete, and  ver ifiabl e from  source 
document
s; that the safety a nd rights of par ticipants are being protected; and that the cl inical trial 
is being conducted in accordance wi th the currently approved protocol and any othe r clinical trial 
agreements, I CH G CP, and  all appl icabl e regulatory r equir ements. 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 75 of 84 10.6. Source Documents  
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the Investigator’s site.  
Data reported on the CRF  or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
Investigator may need to request previous medical records or transfer records, depending on the 
clinical trial.  
The required source data should include sequential notes containing at least the following 
information for each participant:  
• participant ide ntification  (name,  date of birth, sex) 
• docum entation  that participa nt meets eligibility  criteria,  ie, history, physical 
exam ination, and confirmation of diagnosis (to support inclu sion and exclu sion 
criteria) 
• particip ation in trial (including trial number)  
• trial discussed  and date of inform ed consent 
• dates  of all visits  
• docum entation  that protocol- speci fic procedures were  performed 
• results  of efficacy  parameters,  as required  by the protocol 
• start and end date (inclu ding dose regimen) of trial medicatio n (prefera bly drug 
dispensing and return  should be docum ented  as well)  
• record  of all AEs and other safety  parameters (start and end date,  and preferably 
including causality  and intensity)  
• conco mitant medicatio n (includin g start and end date,  dose if relevant;  dose changes 
should be motivated) 
• date of trial completio n and reaso n for early  discontinuation, if applicable 
10.7. Clinical Trial Files and Retention of Records  
The Investigator must maintain adequate and accurate records to enable the conduct of the clinical trial to be fully documented and the clinical trial  data to be subsequently verified. These 
documents should be classified into at least the following 2 categories: (1) Investigator’s clinical trial file, and (2) participant clinical source documents.  
The Investigator’s clinical trial file will contain the  protocol/amendments, CRF and query forms, 
IRB and governmental approval with correspondence, informed consent, drug records, staff curriculum vitae and authorization forms, and other appropriate documents and correspondence.  
All clinical trial documents must be retained by the Investigator until at least 2 years after the last 
approval of a ma
rketing application in an ICH region ( ie, United Stat
es, Europe, or Japan) and 
until there a
re no pending or contemplated marketing applications in an ICH region; or,  if no 
application is filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and regulatory authorities have been notified. Investigators may be 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 76 of 84 required to retain documents longer if required by applicable regulatory requirements, by local 
regulations, or by an agreement with the Sponsor. The Investigator must notify the Sponsor 
before destroying any clinical trial records.  
Should the Investigator wish to assign the clinical trial records to another party or move them to 
another location, the Sponsor must be notified in advance. If the Investigator cannot guarantee 
this archiving requirement at the clinical trial site for any or all of the documents, special 
arrangements must be made between th e Investigator and the Sponsor to store these in sealed 
containers outside of the site so that they can be returned sealed to the Investigator in case of a 
regulatory audit.  
10.8. Clinical Trial and Site Closure  
The Sponsor reserves the right to close the clinic al trial site or terminate the clinical trial at any 
time for any reason at the sole discretion of the Sponsor. Clinical trial sites will be closed upon 
clinical trial completion. A clinical trial site is considered closed when all required documents 
and c linical trial supplies have been collected and a clinical trial  site closure visit has been 
performed. 
The Investigator may initiate clinical trial site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a clinical trial site by the Sponsor or Investigator may include 
but are not limited to:  
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by the Investigator  
• Discontinuation of further study drug development  
10.9. Clinical Study Report  
A CSR will be prepared and provided to the regulatory agency(ies). The Sponsor will ensure that 
the report meets the standards set out in the ICH Guideline for Structure and Content of Clinical 
Study Reports (ICH E3). An abbreviated report may be prepared as applicable.  
10.10.  Publication Policy  
The results of this clinical trial may be published or presented at scientific meetings. If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.  
The Sponsor will comply with the requirements for publication of clinical trial results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multi -center  studies only in their entirety and not as individual site data. In this 
case, a coordinating Investigator will be designated by mutual agreement.  
Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Journal Editors authorship requirements.  
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 77 of 84 11. REFERENCES
Bhatia KP, B ain P , Bajaj N , Elble RJ, H a llett M , Loui s E D, R a ethjen J , Stamelou  M, Testa C M, 
Deuschl  G. T remor Task F orce of t he International P arkinson and Movement Disorder Society.  
Consensus S tatement on  the cla ssification  of tre mors. from the task force on tr emor of the 
International Parkinson and Movement Di sorder Society. Mov Disord . 2018; 33:75- 87. 
Deuschl G, R aethjen J , Hellrie gel H , Elble R . Treatment of  patients w ith essential tremor. Lancet 
Neurol . 2011; 10:148- 161. 
Dieterle F, S istare F, G oodsaid F , Papaluca M, O z er JS, Webb  CP, Baer W, S enagore A, 
Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, Laurie D, 
Harpur E, Sonee M, Ennulat D, Holder D, Andrews -Cleavenger D, Gu YZ, Thompson KL, 
Goering P
L, Vidal J M,  Abadie E, M aciulaitis R , Jacobson -Kram D , Def elice AF, H ausner E A, 
Blank M
, Thompson A, Har low P, Throckmorton D, Xiao S, Xu N, Taylor W, Vamvakas S, 
Flamion B, Lima BS, Ka sper P, Pasanen M, Prasad K, Troth S, Bounous D, Robinson- Gravatt D , 
Bett on G, Davis MA, Akunda J, McDuffie JE, Suter L, Obert L, Guffroy M, Pinches M, Jayadev 
S, Blomme EA, Beushausen SA, Barlow VG, Collins N, Waring J, Honor D, Snook S, Lee J, 
Rossi P, W alker E , Ma ttes W . Renal biomarker qu alification  subm ission: a di alog between t he 
FDA- EMEA and Predictive Safet y Testing Consortium. Nat Biote chnol . 2010; 28:455- 462. 
Elble RJ. The Essential T remor  Rating  As sessment S cale. J Neurol Neuromed. 2016; 1:34- 38. 
El
ias WJ, Lipsman N, Ondo WG, Ghanouni P, Kim YG, Lee W, Schwartz M, Hynynen K, 
Lozano AM, Shah BB, Huss D, Dal lapiazza RF, Gwinn R, Witt J, Ro S, E isenberg HM, Fishman 
PS, Gandhi D, Halpern CH, Chuang R, Butts Pauly K, Tierne y TS, Ha yes MT, Cosgrove GR, 
Yamaguchi T, Abe K, Taira T, Chang JW. A Randomized Trial of Focused Ultra sound 
Thalamotomy f or Essential Tremor. N E ngl J Med . 2016; 375:730- 739. 
Farinde A. Benzodiazepine Equivalency Table. 2018; 
https://emedicine.medscape.com/article/2172250-o verview. 
G
uy W. As sessment Manual for Psychopharmacology: Clinical Global Impression (CGI). Vol 
76-338. Rockville, MD: US Dept of Health Education and Welfare; 1976.
Handforth A, Homanics GE, Covey DF, Krishnan K, Le e JY, Sakimura K, Martin FC, Quesada 
A. T-type cal
cium channel ant agonists suppress tremor in two mouse models of es sential tremor. 
N
europharmacology . 2010; 59:380- 387.
Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, He rzog CA, 
Joannidis M, Kribben A, Levey AS, Ma cLeod AM, Mehta RL, Murray PT, Naicker S, Opal SM, 
Schaefer F, Schetz M, Uchino S. Kidney diseas e : Improving global outcomes (KD IGO) acute 
kidne y injury wor k group. KDIGO cl inical practice guideline for acute kidney injury. Kidney 
International Suppl ements . 2012; 2:1-138. 
Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on 
the worldwide prevalence of es sential t remor. Mov Disord . 2010; 25: 534-541. 
Park YG, P ark HY, L ee CJ,  Choi S, Jo S, Choi H, Kim YH, Shin HS ,  Llinas R R, Kim D. 
Ca(V)
3.1 is a tremor rhythm pacemaker in the inferior olive. Proc Natl Acad Sci U S A. 
2010;107:
10731-10736. 
Park Y G, Kim J, K im D. The pot ential r oles of  T-type Ca2+ channels in motor coor dination. 
Front Neural C ircuits . 2013; 7:172. 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 78 of 84 Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin 
GA, Greenhill L, Shen S, Mann JJ. The Columbia -Suicide Severity Rating Scale: initial validity 
and internal consistency findings from three multisite studies with adolescents and adults. Am J 
Psychiatry . 2011;168:1266-1277. 
Rinn JL, Rozowsky JS, Laurenzi IJ, Petersen PH, Zou K, Zhong W, Gerstein M, Snyder M. Major molecular differences between mammalian sexes are involved in drug metabolism and renal function. Dev Cell . 2004 Jun 6(6):791-800 
Ruoppolo M, Caterino M, Albano L , Pecce R, Di Girolamo MG, Crisci D, Costanzo M, Milella 
L, Franconi F, Campesi I. Targeted metabolomic profiling in rat tissues reveals sex differences. 
Sci Rep . 2018 Mar 16  8(1):4663 
Sabolić, I Asif, A.R., Budach, W.E. et al. Gender differences in kidney function. Pflugers Arch - 
Eur J Physiol  2007;455:397-429 
Trevisan A, Chiara F, Mongillo M, Quintieri L, Cristofori P. Sex -related differences in renal 
toxicodynamics in rodents. Expert Opin Drug Metab Toxicol . 2012 Sep  8(9):1173-1188 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 79 of 84 12. APPENDICES  
APPENDIX  1. CLINICAL LABORATORY EVALUATIONS  
The tests detailed in Appendix Table 1  will be performed by a central laboratory.  
Protocol- specific requirements for inclusion or exclusion of participants are detailed in Section 5  
of the protocol.  
Additional tests may be perfor med at any time during the clinical trial as determined necessary 
by the Investigator or required by local regulations.  
Appendix Table 1 : Protocol -Required Laboratory Assessments  
Clinical Chemistry  Hematology Urinalysis  
Alanine aminotransferase (ALT)  
Alkaline phosphatase  
Aspartate aminotransferase (AST)  
Bicarbonate 
Blood urea nitrogen (BUN)  
Calcium  
Chloride 
Creatinine  
Glucose 
Potassium  
Sodium Total and direct bilirubin  
Total protein  Hematocrit  
Hemoglobin 
Mean corpuscular hemoglobin 
Mean corpuscular hemoglobin 
concentration  
Mean corpuscular volume  
Platelet count  
Red blood cell (RBC) count  
RBC distribution width  
White blood cell (WBC) count  
WBC differential (absolute):  
o Basophils 
o Eosinophils 
o Lymphocytes 
o Monocytes 
o Neutrophils Bilirubin  
Glucose 
Ketones  
Leukocyte esterase  
Nitrite  
Blood 
pH 
Specific gravity  
Protein  
Urobilinogen 
Microscopic exam including 
bacteria, casts, crystals, 
epithelial cells, RBCs, and 
WBCs ( if protein, leukocyte 
esterase, nitrite, or blood is positive) 
Drug Screen  Coagulation Factors  
(Screening only)  Other Tests  
Including but not limited to:  
Amphetamines  
Barbiturates  
Benzodiazepines (Stable use of ≤2 mg of lorazepam/day is 
allowed)  
Cannabinoids (THC)  
Cocaine (metabolite) 
Methadone Opiates  
Phencyclidine Activated partial thromboplastin 
time 
Prothrombin time and international normalized ratio  Serum and urine pregnancy, 
(women of childbearing 
potential only)  
Viral Serology Screen (at Screening only): Hepatitis B surface antigen (HBsAg) and Hepatitis C virus (HCV) 
antibody and HIV antibody/antigen 
Urinary albumin  
Urinary creatinine (Part A 
only) 

Praxis Precision Medicine s Protocol PRAX-944 -221, Version 6.0 
APPENDIX 2. ADVERSE EVENTS: DEFI NITIONS AND PROCED URES 
FOR RECORDING, EVALUATING, FOLLOW-UP, AND 
REPORTING 
Definition of Adverse Events 
AE Definition 
• An AE is any untoward medic al occunence in a patient or clinical trial pruticipant , tempora lly 
associated with the use of study chug, whether or not considered related to the study chug. 
• NOTE : An AE can therefore be any unfavorable and unintended sign (including an abnormal 
labora tory finding ), symptom, or disease (new or exacerba ted) tempo rally associated with the use 
of study drng. 
Events Meeting the AE Definition 
• Any abnormal laborator y test results (hem atology , clinical chemi stry, or minal ysis) or other safety 
assessments (eg, ECG , radi ological scans, vital signs measurement s), includ ing those that worsen 
from baseline, considered clinically significan t in the medical and scientific judgemen t of the 
Investigat or (ie, not related to progression of underl ying disease). 
• Exacerbation of a chronic or intermi ttent pre-existing condi tion including either an increase in 
frequenc y and/or intensity of the condi tion. 
• New condit ions detec ted or diagnosed after study chug administration even though it may have 
been present before the start of the clinical trial. 
• Signs, symptom s, or the clinical sequelae of a suspected chug-ch11 g interaction. 
• Signs, symptom s, or the clinical sequelae of a suspected overdo se of either study chug or a 
concomi tant medic ation. Overdo se per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/ self-hruming intent. Such overdoses should be 
reported regru·dless of sequelae. 
• For efficac y studie s: "Lack of efficac y" or "failure of expec ted phrum acological action" per se will 
not be reported as an AE or SAE. Such instances will be captured in the efficacy assessment s. 
However , the signs, symptom s, and/or clinica l sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfil the defin ition of an AE or SAE. 
Events NOT Meeting the AE Definition 
• Any clinic ally significan t abnorm al labora tory findings or other abnormal safety assessments which 
ru·e associated with the underl ying disease, unless judged by the Investigator to be more severe than 
expec ted for the prutic ipant's condition. 
• The disease/disorder being studied or expec ted progre ssion, signs, or symptoms of the 
disease/disorder being studied , unless more severe than expec ted for the pruticipan t's condit ion. 
• Medical or surgic al procedure (eg, endoscopy, appendec tomy): the condi tion that leads to t he 
procedure is the AE. 
• Situa tions in which an untow ru·d medical occmTence did not occur (social and/or convenience 
admission to a hospital). 
• Anticipated day-to-day fluctuation s of pre-exi sting disease(s) or condi tion(s) present or detected at 
the strut of the clinical tI'ial that do not worsen. 
Confiden tial Page 80 of84 
Praxis Precision Medic ines Protocol PRAX -944-221, Version 6.0 
Definition of SAE 
If an event is not an AE per definition above , then it cannot be an SAE even if s erious conditions 
are met (eg, hospit alizat ion for signs/symptoms of the disease under study, death due to 
prog ression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose: 
a. Results in death 
b. Is life-threatening 
• The t e1m 'life-threatening' in the definition of'sedou s' refers to an event in which the participant 
was at 1 isk of death at the time of the event. It does not refer to an event, which hypo thetically 
might have caused death , if it were more severe . 
C. Require s inpatient hospitalization or prolongation of existing hospitalization 
• In genera l, hospitalization s ignifies that the participant has been detained (usually involving at least 
an overn ight stay) at the hospital or emerge ncy wai·d for obse1vation an d/or treatment t hat would 
not have been approp1iate in the physician's office or outpa tient setting. Comp lications that occur 
dming hos pitalization are AEs. If a complication prolo ngs hospitalization or fulfills any other 
se1iou s cdte1ia , the event is se1ious. When in doubt as to whether "hospitalization" occuned or was 
necessa1y, the AE should be considered se1ious. 
• Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline 
is not considered an AE. 
d. Results in persistent disability/incapaci ty 
• The te1 m disability means a sub stantial dismption of a person's ability to conduct n01mal life 
functions. 
• This defm ition is n ot intended to include expe1ience s of relatively minor medical significance such 
as uncomp licated headache , nausea, vomitin g, diaiThea, influenza, and accident al tra uma ( eg, 
sprained ankle ) which may interfere with or preve nt eve1 yday life functions but do not constitute a 
substantia l dismption. 
e. Is a c ongenital anomal y/birth defect 
f. Important Medical Event: 
• Medical or scienti fic judgement should be exerci sed in decidin g whether SAE repo1ti ng is 
appropriate in other situations su ch as impo1tant medical event s that may not be immedia tely life-
threatening or result in death or hospitalization but may jeopardize the pa1ticipant or may require 
medical or surgical inte1ventio n to preve nt one of the other outcome s listed in the above definition. 
These events should usually be considered sedou s. 
• Example s of such events include invasive or malignan t cancer s, intens ive treatment in an 
emer gency room or at home for allergic b ronchospasm, blood dyscrasias or convulsions t hat do not 
result in hospit alization, or developme nt of dmg dependency or dmg abuse. 
Confidential Page 81 of 84 
Praxis Precision Medic ines Protocol PRAX -944-221, Version 6.0 
Recording and Follow-Up of AE and/or SAE 
AE and SAE Recording 
• When an AE/SAE occurs, it is t he responsib ility of the Investigator to review all docume ntation 
(eg, hospit al progre ss notes, lab orato1y reports, and diagno stics reports) related to the event. 
• The Investigator will then record all relevan t AE/SAE info1ma tion in the CRF. 
• It is not accept able for the Investigator to send p hotoco pies of the pa1ticipant's medical record s in 
lieu of completion of the AE/SAE CRF page. 
• There may be instances when copie s of medical record s for ce1 tain cases are requested. In this case, 
all paiticipant identifier s, with the exception of the paiticipant number , will be redacted on the 
copies of the medical records before submi ssion. 
• The Investigator will attempt to establish a dia gnosis of the event based on signs, symptom s, and/or 
other clinical info1mation. Whenever possible, the diagno sis (not the individua l signs/symptom s) 
will be docume nted as the AE/SAE. 
Assessment of Intensity 
The Investigator will make an assessment of intensity for each AE and SAE reported dudng the clinical 
tiial and assign it to one of the following categories: 
• Mild : An event that is easily tolera ted by the pa1ticipant, causing minimal discomfo1t and not 
inte1fe1ing with eve1yday activities. 
• Moderate : An event that causes sufficient discomfo 1 t and interfere s with n01mal eve1yday 
activi ties. 
• Severe : An event that prevents n01mal eve1yday activities. An AE that is assessed as severe should 
not be confu sed with an SAE. Severe is a catego1y utilized for rating the intensity of an event ; and 
both AEs and SAEs can be assessed as severe. 
An event is defined as 'serious' when it meets at least 1 of the predefi ned outcome s as described in the 
defin ition of an SAE, NOT when it is rated as severe . 
Assessment of Causality 
• The Investigator is obligated to assess the relationship betwee n study dmg and each occune nce of 
each AE/SAE. 
• A " reasonable possibility" of a relationship conve ys that there ai·e facts, evide nce, and/or ai· guments 
to suggest a causal relations hip, rather than a relationship cannot be mled out. 
• The Investigator will use clinical judgement to dete1mine the relationship. 
• Alterna tive causes, su ch as underl ying disease(s), conco mitant therap y, and other risk factors, as 
well as the temporal relationship of the event to study dmg administration will be considered and 
investigated. 
• The Investigator will also consult the Investigator's Brochure (IB) and/o r Produc t Info1ma tion, for 
marke ted produc ts, in his/her assessment. 
• For each AE/SAE, the Investigator must docume nt in the medical notes that he/she has reviewed 
the AE/SAE and h as provided an assessment of causality. 
• There may be situatio ns in w hich an SAE has occlllTed and the Investigator has minimal 
info1mation to include in the initial repo1t. However , it is very important that the Investigator 
alwa ys make an assessment of causality for every eve nt before the initial transmission of the 
SAE data. 
• The Investigator may change his/her opinion of causality in light of follow-up info1mation and send 
an SAE follow-up report with t he updated causality assessment. 
Confidential Page 82 of84 
Praxis Precision Medicine s Protocol PRAX-944 -221, Version 6.0 
• The causali ty assessment is one of the criteria used when dete1mining regulato1y repo1ting 
requiremen ts. 
• A medic ally qualified Investigator must assess the relationship of any AE (includin g SAEs) to the 
use of the study diug, as related or not related, based on clinical judge ment and using all available 
info1ma tion, and may include consideration of the following factor s: 
o Possible alternative causes of the AE, including the disease under treatmen t, pre-exi sting 
conditions, concom itant use of other diugs, and presence of environmen tal or genet ic factors. 
o The tempora l association between study diug exposure and onset of the AE. 
o Whether the manife stations of the AE are consistent with known actions or t oxicity of the 
study diug. 
o The AE resolved or improved with decrea sing the dose or stopping use of the study diug 
(dechallenge ). Judgement should be used if multiple produc ts are discontinued at the same 
time. 
• The causal relationship between the study diug and the AE will be assessed using one of the 
following categories: 
o Not Related: Factor s consistent with an assessment of Not Related include : 
• Temporal relationship is lacking (eg, the event did not occur within a 
reasonable time frame followin g admini stration of the study diug); or 
• Ot her causative factors more likely explain the event (eg, a pre-exi sting 
condit ion, other concomi tant treatments). 
o Related: Fact ors consistent with an assessment of Related include : 
• There is a positive temporal relation ship (eg, the event occuned within a 
reasonable time frame followin g admini stration of study diug); or 
• The AE is more likely explained by the investigational produc t than by another 
cause ( ie, the AE shows a pattern consistent with previous knowledge of the 
investigational product or the class of the study di11g). 
Follow-up of AEs and SAEs 
• The Investigator is obliga ted to pe1fo1m or a1rnnge for the conduc t of supplemen tal measurement s 
and/or evaluations as medicall y indica ted or as requested by the Spon sor or Medical Moni tor to 
elucida te the nature and/or causality of the AE or SAE as fully as possible. This may include 
additional laborato1 y tests or investigations, histopathologic al examina tions, or consultation with 
other health care profe ssionals. 
• New or updated info1m ation will be recorded in the originall y comp leted CRF. 
• The Investigator will submit any updated SAE data within 24 hours of receipt of the info1m ation. 
Reporting of SAEs 
SAE Reporting 
• Email transmission of the SAE fo1m is the prefened method to transmit this info1mation. 
• Initial notifica tion via telephone does not replace the need for the Investigator to complete and sign 
the SAE fo1m within the designated repo1ting time frame s. 
• Contac t Info1m ation for SAE repo1ting: Safety@novo tech-cro .com 
Confiden tial Page 83 of84 
Praxis Precision Medicines  Protocol PRAX -944- 221, Version 6.0  
Confidential Page 84 of 84 APPENDIX  3. ACCEPTABLE BENZODIAZEPINES F OR 
CONCOMITANT USE  
Benzodiazepine Equivalency  
Approxim ately 
Equivalent Oral 
Dose, mg  Time to Peak Level, 
hours  Half -life, hours  
Alprazolam (Xanax)  ≤1 1-2 12 
Bromazepam (Lexotan)  ≤6 1-4 20 
Chlordiazepoxide (Librium)  ≤25 1-4 100 
Clonazepam (Klonopin) ≤0.5 1-4 34 
Clorazepate (Tranxene)  ≤15 0.5-2 100 
Diazepam (Valium)  ≤10 1-2 100 
Flurazepam (Dalmane)  ≤30 0.5-1 100 
Lorazepam (Ativan)  ≤2 1-4 15 
Nitrazepam (Mogadon)  ≤10 0.5-2 30 
Oxazepam (Serax)  ≤30 1-4 8 
Quazepam (Doral)  ≤20 1.5 25-41
Temazepam (Restoril)  ≤20 2-3 11
Triazolam (Halcion)  ≤0.5 1-2 2
Adapted from: Farinde A. Benzodiazepine Equivalency Table 2018 [cited 2018 December 20]. Available from: 
https://emedicine.medscape.com/article/217 2250-overview (Farinde 2018) 